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ABSTRACT OF THE DISSERTATION 
Synthesis of Clickable Poly(ethylene glycol) Derivatives for Fabrication of Modular 
Microsphere-Based Scaffolds to Promote Vascularization 
by 
Peter Khoatan Nguyen 
Doctor of Philosophy in Biomedical Engineering 
Washington University in St. Louis, 2015 
Professor Donald Elbert, Chair 
 
 Vascularization plays an important role in supporting transplanted tissues and cells in 
tissue engineering applications.  Most tissues require access to blood vessels for the delivery of 
oxygen and nutrients, as well as the removal of carbon dioxide and cellular waste products.  
Without an adequate blood supply, cells within tissue-engineered constructs and scaffolds lose 
viability and fail to perform their intended functions.  The goal of this dissertation was to design 
scaffolds that can promote vascularization of biomaterial implants for biomedical applications.  
In order to accomplish this goal, clickable poly(ethylene glycol) (PEG) derivatives were 
synthesized in order to fabricate modular microsphere-based scaffolds that could deliver 
angiogenic growth factors and molecules.  Microspheres were formed by lowering the lower 
critical solution temperature (LCST) of PEG, inducing thermal phase separation, and forming 
spherical PEG-rich domains that increased in size until they reached the gel point.  Using a 
PEG/dextran aqueous two-phase system, microspheres were crosslinked via click reactions to 
form scaffolds.  Conjugation of these scaffolds with cell adhesion peptides and proteins allowed 
for cell attachment and migration.  Subsequently, scaffolds were formed in the presence of cells 
to confirm cell attachment and demonstrate that the functionalized PEG and the scaffold 
 xi 
 
fabrication process did not affect cell viability.  To show that the scaffolds did not adversely 
affect the activity of loaded growth factor, biologically active vascular endothelial growth factor 
(VEGF) was successfully loaded into and delivered from the scaffolds in an endothelial cell 
migration assay.  Finally, fibroblasts and endothelial cells were seeded into the scaffolds to 
determine if the scaffolds were able to support vascular formation.  After 21 days, the scaffolds 
demonstrated small regions of vascularization.  The vascularization in these scaffolds was 
comparable to what we had observed with similar scaffold implants in mice.  To improve 
scaffold vascularization, future work will be done to adjust their porosity, growth factor delivery, 
and introduce scaffold degradability.  Overall, this dissertation demonstrated that clickable PEG 
microsphere-based scaffolds have excellent potential for inducing vascularization in tissue 
engineering applications. 
 
 
 1 
 
 
Chapter 1 
Introduction 
1.1 Overview and Objectives of Dissertation 
Providing a robust vascular network is required for the survival of transplanted and 
engineered tissues, as the diffusion of oxygen and nutrients alone is not adequate for cell survival 
in thicker tissues or tissue-engineered constructs (Rouwkema, Rivron et al. 2008; Lovett, Lee et 
al. 2009; Phelps and García 2010; Novosel, Kleinhans et al. 2011; Chu and Wang 2012; Auger, 
Gibot et al. 2013; Birbrair, Zhang et al. 2014).  Most tissues require a highly branched system of 
larger blood vessels and smaller capillaries to supply oxygen and nutrients (Rouwkema, Rivron 
et al. 2008; Lovett, Lee et al. 2009; Phelps and García 2010; Novosel, Kleinhans et al. 2011; Chu 
and Wang 2012; Auger, Gibot et al. 2013; Birbrair, Zhang et al. 2014).  The tissues that do not 
require a dedicated vascular system, namely skin, cartilage, and cornea, are supplied with oxygen 
and nutrients from diffusion through a nearby system of blood vessels and capillaries 
(Rouwkema, Rivron et al. 2008; Lovett, Lee et al. 2009; Phelps and García 2010; Novosel, 
Kleinhans et al. 2011; Chu and Wang 2012; Auger, Gibot et al. 2013; Birbrair, Zhang et al. 
2014).  The diffusion limit of oxygen limits the maximum distance of blood vessels and 
capillaries from tissues to 200 µm.  However, implanted tissues are usually located at an 
insufficient distance from those blood vessels and capillaries (Rouwkema, Rivron et al. 2008; 
Lovett, Lee et al. 2009; Phelps and García 2010; Novosel, Kleinhans et al. 2011; Chu and Wang 
2012; Auger, Gibot et al. 2013; Birbrair, Zhang et al. 2014).  To overcome the diffusion limit, 
 2 
 
 
several strategies can be employed to provide blood vessels and capillaries to the tissues, 
including cell-based angiogenesis and scaffold based strategies (Rouwkema, Rivron et al. 2008; 
Lovett, Lee et al. 2009; Phelps and García 2010; Novosel, Kleinhans et al. 2011; Chu and Wang 
2012; Auger, Gibot et al. 2013; Birbrair, Zhang et al. 2014).  The objective of this dissertation is 
to create scaffolds with poly(ethylene glycol) (PEG) microspheres that can support a vascular 
network to provide a blood supply to transplanted tissues and tissue-engineered constructs.     
We approached this problem with a scaffold based strategy that also incorporates 
concepts from cell-based angiogenesis.  Scaffolds are formed in a modular manner, and they 
require the synthesis of several different PEG derivatives (Nichols, Scott et al. 2009; Scott, 
Nichols et al. 2010; Smith, Segar et al. 2012; Nguyen, Snyder et al. 2013).  Each PEG derivative 
has a different functional end group, which allows for complementing PEG derivatives to 
crosslink together to form PEG microspheres (Nichols, Scott et al. 2009; Scott, Nichols et al. 
2010; Elbert 2011; Elbert 2011; Smith, Segar et al. 2012; Nguyen, Snyder et al. 2013).  We 
developed a method to synthesize PEG derivatives with two functional end groups per PEG 
molecule.  These multifunctional PEG derivatives served the same purpose for creating PEG 
microspheres, but had greater versatility with two functional groups.  PEG microspheres can then 
be crosslinked together to form a scaffold upon centrifugation (Scott, Nichols et al. 2010; Elbert 
2011; Elbert 2011; Smith, Segar et al. 2012; Nguyen, Snyder et al. 2013).  Different types of 
microspheres can be incorporated during centrifugation to create modular scaffolds with 
different properties (Scott, Nichols et al. 2010; Smith, Segar et al. 2012; Nguyen, Snyder et al. 
2013).  Incorporating degradable microspheres (porogenic microspheres) increases the porosity 
of the scaffolds while introducing other microspheres with special functional groups allows for 
the incorporation of cell adhesion molecules and proteins to promote cell attachment (Scott, 
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Nichols et al. 2010; Smith, Segar et al. 2012; Nguyen, Snyder et al. 2013; Roam, Nguyen et al. 
2014).  The versatile nature of the scaffolds also provides the option for modification with 
proteins and molecules for controlled drug delivery through affinity interactions (Wacker, Scott 
et al. 2006; Scott, Nichols et al. 2010; Roam, Nguyen et al. 2014).  Modifications that can be 
introduced include the addition of RGD peptide, laminin, heparin, and bovine serum albumin 
(BSA).  In addition to their versatility, these scaffolds are designed to prevent unwanted cell and 
protein interactions under physiological conditions through the use of functional groups that 
undergo specific reactions, such as bioorthogonal click reactions (Iha, Wooley et al. 2009; Nwe 
and Brechbiel 2009; Nguyen, Snyder et al. 2013).  By combining versatility of the PEG 
derivatives with the modular scaffold fabrication process, porous PEG scaffolds were formed 
that could provide controlled release of growth factors for vascularization.  To assess the 
effectiveness of these scaffolds for vascularization, they were either implanted subcutaneously 
into mice or co-cultured with fibroblasts and endothelial cells. 
 
1.2 Vascularization 
Without blood vessels, tissues cannot grow beyond the diffusion limit of oxygen, which 
is 100-200 µm (Carmeliet and Jain 2000; Rouwkema, Rivron et al. 2008; Novosel, Kleinhans et 
al. 2011; Auger, Gibot et al. 2013).  Blood vessels not only provide cells and tissues access to 
oxygen, but they also provide nutrients and remove carbon dioxide and cellular waste products 
(Carmeliet and Jain 2000; Rouwkema, Rivron et al. 2008; Novosel, Kleinhans et al. 2011; 
Auger, Gibot et al. 2013).  While larger tissue-engineered constructs can be supplied with 
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nutrients in vitro with the aid of perfusion bioreactors, new blood vessel formation is still 
required for tissue-engineered constructs and scaffolds to be successful post implantation 
(Portner, Nagel-Heyer et al. 2005; Janssen, Oostra et al. 2006; Rouwkema, Rivron et al. 2008).  
Since implants tend to be greater than 200 µm, capillary networks need to be formed within the 
implants.  Following the implantation of scaffolds and tissue-engineered constructs, blood 
vessels from the host invade to form a vascular network as a response to the implant 
(Rouwkema, Rivron et al. 2008).  This type of vascularization, in which new blood vessels form 
from preexisting vascularization, is referred to as angiogenesis (Auger, Gibot et al. 2013; Birbrair, 
Zhang et al. 2014).  Angiogenesis is initiated by growth factor activation of endothelial cells, 
causing basement membrane degradation by proteases and endothelial cell migration and 
proliferation toward the angiogenic stimuli (Carmeliet and Jain 2011).  This is followed by 
sprout formation and extension, lumen formation, and vessel maturation with pericytes 
(Carmeliet and Jain 2011).  New formation of blood vessels without any preexisting vasculature 
is referred to as vasculogenesis, and it normally occurs during embryologic development (Auger, 
Gibot et al. 2013).  Vasculogenesis is similar to angiogenesis but begins with growth factor 
activation of angioblasts and haemangioblasts, followed by growth factor mediated vessel 
assembly, and finally activation of receptors to transition into angiogenesis (Demir, Seval et al. 
2007).  Despite the spontaneous blood vessel ingrowth that occurs in conventional implants, the 
complete vascularization takes several weeks because vessel growth is limited to tenths of 
micrometers a day (Clark and Clark 1939).  Moreover, slow vascularization may lead to non-
uniform cell integration, with higher cell densities within the outer regions of the scaffold 
(Malda, Rouwkema et al. 2004).  Successfully promoting quick and complete vascularization in 
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biomaterial scaffolds and tissue-engineered constructs will expand scaffold applications in tissue 
engineering. 
Many growth factors and bioactive molecules come into play for promoting different 
stages of angiogenesis.  Some of the growth factors and bioactive molecules involved in 
promoting vascularization include angiopoietin-1, angiopoietin-2, fibroblast growth factor, 
platelet-derived growth factor, vascular endothelial-cadherin, sphingosine-1-phosphate (S1P), 
and vascular endothelial growth factor (VEGF) (Conway, Collen et al. 2001; Wacker, Scott et al. 
2006).  The two that we will focus on for drug delivery in this work are S1P and VEGF. 
 
1.2.1 Sphingosine-1-Phosphate 
The bioactive lipid S1P is an appealing biological factor because it has been shown to be 
a powerful and complete angiogenic regulator of endothelial cell function, promoting cell 
survival, proliferation, migration, barrier integrity, and angiogenic differentiation (Liu, Wada et 
al. 2000; Allende, Yamashita et al. 2003; McVerry and Garcia 2005; Wacker, Scott et al. 2006; 
Lucke and Levkau 2010).  By interacting with the family of G protein-coupled receptors called 
S1P receptors (formally known as endothelial differentiation gene (Edg) receptors), S1P can 
trigger key endothelial cell behaviors that improve vascularization (Lee, Van Brocklyn et al. 
1998; Liu, Wada et al. 2000; Allende, Yamashita et al. 2003; Kono, Mi et al. 2004; Lucke and 
Levkau 2010).  S1P has been shown to promote endothelial cell migration during platelet 
activation (English, Welch et al. 2000), and cause a dose-dependent enhancement of endothelial 
cell migration (Liu, Verin et al. 2001).  At physiological concentrations, S1P has been shown to 
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inhibit smooth muscle cell migration (Boguslawski, Grogg et al. 2002; Tamama, Tomura et al. 
2005).  S1P may also inhibit recruitment of endothelial cells by decreasing their permeability, 
stabilizing intracellular junctions in a concentration-dependent manner (McVerry and Garcia 
2005; Gavrilovskaya, Gorbunova et al. 2008; Tengood, Kovach et al. 2010).  Research has 
shown that S1P1 receptor knockout mice exhibit a lethal phenotype with severe hemorrhaging, 
indicating that S1P is required at later stages of angiogenesis for vessel maturation (Liu, Wada et 
al. 2000; Allende, Yamashita et al. 2003; Kono, Mi et al. 2004).  Controlling the release of S1P 
is therefore crucial to enhancing vascularization. 
 
1.2.2 Vascular Endothelial Growth Factor 
Another desirable factor for vascularization is VEGF because of its association with 
promoting angiogenesis and endothelial cell migration.  Mammals have five members in the 
VEGF family: VEGF-A, VEGF-B, VEGF-C, VEGF-D and placenta growth factor (PLGF) 
(Holmes, Roberts et al. 2007).  In angiogenesis, VEGF normally refers to VEGF-A due to its 
importance in vascular development (Holmes, Roberts et al. 2007).  More specifically, VEGF 
has been shown to play an important role as an endothelial cell specific growth factor that 
stimulates endothelial cell migration, proliferation, and nitric oxide release, allowing 
angiogenesis to take place (Conway, Collen et al. 2001; Kliche and Waltenberger 2001; 
Barrientos, Stojadinovic et al. 2008).  The effects of VEGF are mediated mainly by two tyrosine 
kinase cell receptors, VEGFreceptor-1 (VEGFR-1) and VEGFrecepter-2 (VEGFR-2), that trigger 
signaling pathways upon binding VEGF (Kliche and Waltenberger 2001).  The role of VEGFR-1 
in angiogenesis is not completely known.  However, VEGFR-1 may moderate the amount of free 
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VEGF available to bind to VEGFR-2 and prevent vessel overgrowth by competing with 
VEGFR-2 binding (Carmeliet and Jain 2011).  VEGFR-2 is the principal mediator of endothelial 
cell proliferation, migration, survival, and permeability (Holmes, Roberts et al. 2007).  In 
contrast to S1P, VEGF has been shown to be important at early stage angiogenesis by 
upregulating matrix metalloproteinase (MMP)-2 and MMP-9, which results in the destruction of 
the extracellular matrix and destabilizes the blood vessels, promoting vessel infiltration (Sang 
and Douglas 1996; Sang 1998; Bouis, Kusumanto et al. 2006; Gavrilovskaya, Gorbunova et al. 
2008; Tengood, Kovach et al. 2010).  Managing the temporal release of VEGF will play an 
important part in improving vascularization in scaffolds. 
 
1.3 Drug Delivery 
Drug delivery refers to the systems and technologies engineered to transport therapeutic 
agents to specific targets.  It is often used to deliver growth factors and bioactive molecules to 
elicit biological responses, such as angiogenesis, in cells and tissues.  Choosing the appropriate 
growth factors and bioactive molecules and devising a suitable delivery strategy are the main 
aspects of successful drug delivery.  With respect to promoting and enhancing angiogenesis of 
tissue-engineered constructs and scaffolds, drug delivery systems must deliver growth factors 
and bioactive molecules to destabilize existing blood vessel walls and  induce endothelial cell 
proliferation and migration to form sprouts and tube structures (Wacker, Scott et al. 2006).  To 
optimally enhance vascularization, the complete biological response of vascular cells to 
biological factors over time must be addressed.  Therefore, not only are the types of factors that 
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are delivered relevant, but how they are delivered temporally are important considerations that 
need to be made. 
 
1.3.1 Importance of Controlled Release of S1P and VEGF 
 The uncontrolled release of S1P and VEGF can potentially inhibit vascularization in 
scaffolds instead of promoting it.  Determining when to deliver each factor is critical, since the 
process of angiogenesis is organized into a series of events that begin with vessel destabilization, 
followed by endothelial cell proliferation and migration, sprout and tube structure formation, and 
finally vessel maturation (Bouis, Kusumanto et al. 2006; Wacker, Scott et al. 2006).  As 
mentioned previously, VEGF is involved in the early stage of angiogenesis while S1P is required 
for the later stage of angiogenesis (Sang and Douglas 1996; Sang 1998; Liu, Wada et al. 2000; 
Allende, Yamashita et al. 2003; Kono, Mi et al. 2004; Bouis, Kusumanto et al. 2006; 
Gavrilovskaya, Gorbunova et al. 2008; Weiss, Zimmermann et al. 2009; Tengood, Kovach et al. 
2010).  Delivering too much VEGF during the latter stages of angiogenesis results in the 
destruction of the extracellular matrix and destabilization of blood vessels (Sang and Douglas 
1996; Sang 1998; Bouis, Kusumanto et al. 2006; Gavrilovskaya, Gorbunova et al. 2008; 
Tengood, Kovach et al. 2010), and elevated levels of S1P during early and middle stages of 
angiogenesis reduces endothelial cell recruitment and migration (McVerry and Garcia 2005; 
Gavrilovskaya, Gorbunova et al. 2008; Tengood, Kovach et al. 2010).  More importantly, these 
factors play multiple roles in the body (Arsic, Zacchigna et al. 2004; Sattler and Levkau 2009), 
and the unchecked release of factors from scaffolds could lead to other side effects. 
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1.3.2 Strategies for Controlled Release 
A delivery system that releases VEGF and S1P sequentially may provide optimal 
conditions for vascularization in PEG scaffolds.  The main categories of delivery systems include 
diffusion-based, affinity-based, swelling-based, erosion-based, and stimuli-based (Alarcon, 
Pennadam et al. 2005; Oupicky, Bisht et al. 2005; Arifin, Lee et al. 2006; Lin and Metters 2006; 
Wang and von Recum 2011).  We are mainly interested in diffusion-based and affinity-based 
drug delivery systems because they are well suited for the PEG system we will be discussing 
later in this chapter.  Diffusion-controlled delivery systems rely on drug release down a 
concentration gradient while affinity controlled systems use affinity-based interactions, such 
ionic interactions, hydrophobic interactions, hydrogen bonding, or van der Waals forces to 
control drug release (Wang and von Recum 2011).  Implementing diffusion-based drug delivery 
for VEGF will result in a quick release of VEGF that mimics a nonlinear Fickian release profile 
(Amsden 1998; Amsden and Turner 1999; Peppas, Huang et al. 2000; Arifin, Lee et al. 2006; Lin 
and Metters 2006; Wang and von Recum 2011).  However, a system that relies only on passive 
diffusion will normally see the growth factor cleared away relatively quickly (Arifin, Lee et al. 
2006; Lin and Metters 2006).  While the burst release of VEGF is desirable, VEGF release must 
also be sustained for successful angiogenesis.  To achieve sustained release of growth factors, an 
affinity-based approach is needed.  A well-established affinity-based system is the heparin gel 
system formed by crosslinking heparin with PEG (Tae, Scatena et al. 2006).  Heparin is a linear 
polysaccharide that reversibly binds with many proteins through mostly electrostatic interactions 
as well as hydrogen bonding and hydrophobic effects (Sakiyama-Elbert and Hubbell 2000; Tae, 
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Scatena et al. 2006; Nie, Baldwin et al. 2007; Sakiyama-Elbert 2014).  Tae et al. formed these 
PEG-heparin gels by crosslinking the N-hydroxysuccinimidyl ester of PEG-bis-butanoic acid 
with hydrazide-functionalized heparin.  When implanted in mice, these scaffolds demonstrated 
an initial burst release followed by controlled release of VEGF over three weeks that increased 
angiogenesis (Tae, Scatena et al. 2006).  The success of their work means incorporating a similar 
heparin drug delivery system for VEGF in our modular microsphere-based scaffolds may be 
promising for vascularization.   
  An affinity-based drug delivery system will also be suitable for releasing S1P.  However, 
S1P is a bioactive lipid and cannot use heparin as a delivery vehicle.  Instead, it has been shown 
to bind lipoproteins, such as low density lipoprotein and high density lipoprotein (Murata, Sato et 
al. 2000; Alford, Kaneda et al. 2009).  S1P has also been shown to bind globular proteins, such 
as albumin (Murata, Sato et al. 2000).  One successful affinity-based system used BSA as the 
delivery vehicle for S1P (English, Welch et al. 2000; Wacker, Scott et al. 2006; Scott, Nichols et 
al. 2010).  The affinity-based system demonstrated endothelial cells responding to a controlled 
release of S1P (Wacker, Scott et al. 2006; Scott, Nichols et al. 2010).  Due to its success in 
controlled release of S1P, this delivery system was chosen to control the delivery of S1P to 
promote angiogenesis. 
 
1.4 Scaffold Materials 
Construction of scaffolds for tissue engineering has mainly involved the use of hydrogels 
due to their ability to provide a three-dimensional (3D) environment for cell growth that mimics 
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soft tissues.  This allows limited diffusion of nutrients, oxygen, and waste through their elastic 
networks (Lee and Mooney 2001; Hoffman 2002; Zhu 2010).  The two major types of 
biomaterials used to make hydrogels are natural and synthetic biomaterials.  Natural biomaterials 
encompass all natural polymer-based materials, including polysaccharides like hyaluronic acid, 
dextran, and alginate chitosan, and proteins like fibrin, collagen, and gelatin (Zhu 2010).  
Synthetic biomaterials include synthetic polymers, such as polypeptides, PEG, poly(acrylic acid) 
(PAA), poly(vinyl alcohol) (PVA), and polyacrylamide (Zhu 2010).  The advantages of natural 
materials include access to biological functions, such as biodegradation and cell adhesion (Zhu 
2010).  However, the use of natural polymers raises concerns of possible infection, immunogenic 
reactions, and mechanical stability (Nerem and Seliktar 2001; Orban, Wilson et al. 2004; Chen 
and Hunt 2007).  Synthetic biomaterials have a number of advantages over natural biomaterials, 
providing adjustable mechanical properties, controllable chemical compositions, ability for 
photopolymerization, controllable scaffold architecture, biofunctionality, and flexible transport 
properties (Hoffman 2002; Drury and Mooney 2003).  Due to these major advantages, synthetic 
biomaterials have become popular for scaffold formation. 
 
1.4.1 Poly(ethylene glycol) as a Biomaterial 
 PEG is a synthetic polymer composed of ethylene oxide monomers that is sometimes 
referred to as poly(ethylene) oxide.  Its general formula is HO-(CH2-CH2-O)n-H, and it is 
commercially available in a wide range of molecular weights.  Of the many synthetic 
biomaterials available, PEG is a popular FDA-approved hydrophilic polymer for tissue 
engineering due to a number of additional desirable properties including non-immunogenicity, 
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resistance to protein adsorption, good biocompatibility, and versatile functionalization (e.g. vinyl 
sulfone, amine, acrylate, thiol, azide, alkyne, and cyclooctyne) (Lee, Lee et al. 1995; Peppas, 
Keys et al. 1999; Alcantar, Aydil et al. 2000; Elbert and Hubbell 2001; Wacker, Scott et al. 2006; 
Scott, Nichols et al. 2010; Nguyen, Snyder et al. 2013).  A major characteristic of PEG is its 
ability to form a hydration shell that extends several hundred angstroms from the PEG backbone 
by bonding three water molecules per each unit of PEG (Liu and Parsons 1969; Horne, Almeida 
et al. 1971; Kjellander and Florin 1981; Muller and Rasmussen 1991).  The resistance to protein 
adsorption has been attributed to the hydration shell of PEG, the steric repulsion of its polymer 
chains, and the overall neutral charge of PEG (Jeon and Andrade 1991; Jeon, Lee et al. 1991; 
McPherson, Shim et al. 1997; Ostuni, Chapman et al. 2001).  PEG’s high resistance to protein 
adsorption contributes to its non-immunogenic and biocompatibility properties.  Due to these 
characteristics, it does not possess any biological functions that natural materials offer.  In 
addition, PEG can be quite versatile, since it can be modified with a variety of functional groups.  
The wide variety of functional groups available to PEG permits the use of a number of reactions, 
including Michael-type addition (Huang, Michel et al. 2001), click chemistry (Nguyen, Snyder et 
al. 2013), enzymatic reaction (Sperinde and Griffith 1997), native chemical ligation (Hu, Su et al. 
2009), irradiation of linear or branched PEG polymers (Bray and Merrill 1973), free radical 
polymerization (Sawhney, Pathak et al. 1993), mixed-mode polymerizations (Lee, Dalsin et al. 
2002; Salinas and Anseth 2008), and others (Peppas, Keys et al. 1999; Zhu 2010).  PEG 
derivatives can allow even more versatility through introduction of biological functions, such as 
degradability or delivery of biological factors (Zhu 2010).  This gives PEG the same beneficial 
properties found in natural biomaterials, making it the ideal candidate as a biomaterial for 
scaffold fabrication. 
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1.5 Click Chemistry 
Recently, click chemistry has become popular with click reactions replacing widely used 
crosslinking and bio-conjugation chemistries, such as free radical polymerizations, aldehydes 
and their Schiff base intermediates, and Michael-type additions (Hudalla and Murphy 2009).  
Click chemistry usually refers to the copper(I)-catalyzed Huisgen 1,3-dipolar cycloaddition 
reaction, or alternatively the [3+2] azide-alkyne cycloaddition, but it can also refer to the strain-
promoted [3+2] azide-alkyne cycloaddition, the Staudinger ligation, thiol-yne reactions, and 
other types of reactions (Kolb, Finn et al. 2001; Agard, Prescher et al. 2004; Fairbanks, Scott et 
al. 2009; Nwe and Brechbiel 2009).  These are simple reactions that have fast kinetics, high 
yields, mild reaction conditions, insensitivity to oxygen or water, stereospecificity, and 
regiospecificity (Kolb, Finn et al. 2001; DeForest, Polizzotti et al. 2009).  They can be completed 
under physiological conditions to produce physiologically stable products without the risk of 
harmful byproducts (Kolb, Finn et al. 2001; Nwe and Brechbiel 2009).    Click chemistry 
reactions are preferred over other chemistries, which rely heavily on reaction conditions and are 
susceptible to hydrolysis and non-selective conjugation with biomolecule functionalities (e.g. 
amines) (Hudalla and Murphy 2009).  Furthermore, click reactions are rapid and efficient, and 
the products that form are highly stable (Hudalla and Murphy 2009).  Click reactions can also be 
called bioorthogonal because they are highly specific reactions that are biocompatible and not 
susceptible to non-selective conjugations (Prescher and Bertozzi 2005; McKay and Finn 2014).  
However, one disadvantage of the [3+2] cycloaddition reaction widely used in click chemistry is 
the requirement of a copper catalyst in order to perform the reaction efficiently at physiological 
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temperatures and environments.  Copper has been shown to be toxic to bacteria and mammalian 
cells, which precludes the use of this reaction in the presence of cells unless the copper can be 
removed or neutralized (Agard, Prescher et al. 2004).  Fortunately, a viable alternative to 
activating alkynes for catalyst-free [3+2] cycloaddition with azides can be performed using ring 
strain from cycloalkynes, which causes a destabilization of the ground state over the transition 
state to provide an accelerated reaction rate (Shea and Kim 1992; Agard, Prescher et al. 2004).  
Other similar alternatives that are catalyst-free include activated alkyne reactions and electron-
deficient alkyne reactions (Becer, Hoogenboom et al. 2009).  The advantages of click reactions 
make it an important consideration for PEG scaffold formation. 
 
1.6 Scaffold Design  
The success of scaffold implants for vascularization relies upon the choice of scaffold 
materials used, the crosslinking chemistries implemented, and especially the overall scaffold 
design.  Poor scaffold design can easily negate the attributes of the materials and chemistries 
used to create the scaffold.  Ideal properties of scaffolds for tissue engineering include 
biocompatibility, biodegradability or bioresorbability (with degradation or resorption rates that 
match the cellular environment), versatile surface chemistry for the addition of biological 
functions, mechanical properties similar to tissues at the site of implantation, a 3D structure with 
an interconnected pore network, and flexible fabrication process (Hutmacher 2001; Chan and 
Leong 2008).  Of the properties listed, a particularly important design consideration for scaffold 
vascularization is pore size and network.  It has been shown that scaffolds with pores sizes 
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greater than 250 µm have greater vessel ingrowth than those with smaller pore sizes (Druecke, 
Langer et al. 2004).  However, pore size bears no significance if the pores are not interconnected 
to allow cell migration for vascularization.  Large pore sizes in combination with pore 
interconnectivity are required for the success of vascularization in scaffolds (Yang, Leong et al. 
2001; Karageorgiou and Kaplan 2005).  The conventional methods that have been used to create 
porous scaffolds are phase separation (Nichols, Scott et al. 2009; Scott, Nichols et al. 2010; 
Smith, Segar et al. 2012; Nguyen, Snyder et al. 2013), freeze drying (Whang, Thomas et al. 
1995; Whang, Tsai et al. 1998), particulate leaching (Hutmacher 2001), and gas foaming (Harris, 
Kim et al. 1998).  These techniques for fabricating scaffolds have parameters that can be 
manipulated to change the size, shape, and interconnectivity of the pores, but pore organization 
is harder to control (Rouwkema, Rivron et al. 2008).  Recently, solid free-form fabrication 
systems have become popular because they offer better control of the porosity and 
interconnectivity of pores, and the scaffolds formed tend to be well-defined instead of randomly 
patterned (Hutmacher, Sittinger et al. 2004; Hollister 2005).  Another current fabrication 
technique uses dissolvable sacrificial templates that create precise patterned networks (Miller, 
Stevens et al. 2012; Mohanty, Larsen et al. 2015).  Unlike other systems, this fabrication method 
produces precise networks by 3D printing the desired porous network template in a dissolvable 
material like carbohydrate glass or PVA and encapsulating the lattice with a biomaterial before 
dissolving the lattice (Miller, Stevens et al. 2012; Mohanty, Larsen et al. 2015).  This system 
replaces pores with interconnected channels, creating ideal scaffolds for tissue engineering 
applications.  Designing scaffolds with ideal properties has been a challenging balancing act, and 
until recently, creating an ideal interconnected porous network for cells was difficult to achieve.  
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Chapter 2 
Modular Scaffolds Using Poly(ethylene 
glycol) Microspheres for In Vivo 
Vascularization 
 
2.1 Abstract 
Porous modular microsphere-based PEG scaffolds were created to address the need of 
promoting vascularization in vivo for cell and tissue support.  Fabrication of microspheres 
without the use of other surfactants, organic solvents, monomers and polymers was done by 
taking advantage of the lower critical solution temperature (LCST) of poly(ethylene) glycol 
(PEG) in sodium sulfate solutions.  Microspheres were formed by thermally inducing phase 
separation of reactive PEG derivatives in an aqueous solution to create PEG-rich domains that 
coarsen in size until they reach the gel point.  Microspheres were then centrifuged to form 
scaffolds.  Different types of microspheres were used to control the bioactivity and porosity of 
the scaffolds.  Pores in the scaffolds were formed using porogenic PEG microspheres that 
hydrolyze within two days of scaffold formation.  Introducing cell adhesion peptides allowed for 
cells to attach to the scaffold and delivery of sphingosine-1-phosphate (S1P) promoted cell 
infiltration into the scaffold.  Scaffolds were implanted into mice subcutaneously and explanted 
after two weeks to assess vascularization.  Photoacoustic microscopy and H&E staining revealed 
the extent of vascularization of the scaffolds.  We found that PEG scaffolds delivering S1P had 
more vascularization than controls. 
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2.2 Introduction 
 Scaffolds are an important part of tissue engineering because they provide structural 
support for cells and allow for tissue development.  A variety of synthetic biomaterials are used 
to make scaffolds, but the many useful properties of poly(ethylene) glycol (PEG) hydrogels 
make them promising for use as scaffolds in tissue engineering (Scott, Nichols et al. 2010).  
Scaffolds made from PEG have many desirable properties including biocompatibility, resistance 
to protein adsorption, the ability to impart biological functions, and the means for drug delivery 
(Jeon and Andrade 1991; Jeon, Lee et al. 1991; Lee, Park et al. 1991; Alcantar, Aydil et al. 2000; 
Richardson, Peters et al. 2001; DeLong, Moon et al. 2005; Lutolf and Hubbell 2005).  Porous 
PEG hydrogels are optimal for tissue-engineered scaffolds, since their porosity allows for cell 
function and survivability.  (Lutolf and Hubbell 2005; Varghese and Elisseeff 2006; Nguyen, 
Snyder et al. 2013).  Porous scaffolds can be created using several techniques, such as 
incorporating nontoxic porogens or creating macro networks from dissolvable materials 
(Asnaghi, Giglio et al. 1995; Shapiro and Cohen 1997; Lévesque, Lim et al. 2005; Stachowiak, 
Bershteyn et al. 2005; Ford, Bertram et al. 2006; Sannino, Netti et al. 2006; Bryant, Cuy et al. 
2007; Osathanon, Linnes et al. 2008; Miller, Stevens et al. 2012).  Scaffolds can recruit cells and 
promote attachment by delivering bioactive molecules, such as sphingosine-1-phosphate (S1P), 
and imparting biological functions, such as cell adhesion. (Richardson, Peters et al. 2001; 
DeLong, Moon et al. 2005; Lutolf and Hubbell 2005; Wacker, Scott et al. 2006; Scott, Nichols et 
al. 2010).  Incorporating these properties into tissue-engineered scaffolds is one method for 
promoting cell migration and proliferation that will result in scaffold vascularization. 
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 An effective method for engineering the properties of a scaffold is to modularly assemble 
scaffolds with different parts that introduce different properties.  Scaffolds made using the 
modular approach consist of various types of microparticles that have different functionalities or 
characteristics to tailor the scaffold for specific purposes (McGuigan and Sefton 2006; Yeh, Ling 
et al. 2006; Rivest, Morrison et al. 2007; Du, Lo et al. 2008; Pautot, Wyart et al. 2008; Serban 
and Prestwich 2008; Scott, Nichols et al. 2010).  A technique that has been shown to successfully 
form scaffolds with properties tailored for cell survival, attachment, and migration is the 
formation of PEG functional microspheres that can be crosslinked together to form modular 
scaffolds (Nichols, Scott et al. 2009; Scott, Nichols et al. 2010).  This method creates PEG 
microspheres without a surfactant by exploiting the lower critical solution temperature (LCST) 
of PEG derivatives with kosmotropic salts to form PEG-rich domains that coarsen and crosslink 
into microspheres (Bailey and Callard 1959; Bae, Lambert et al. 1991; Nichols, Scott et al. 2009; 
Scott, Nichols et al. 2010; Flake, Nguyen et al. 2011).  These microspheres can then crosslink 
together to form a modular scaffold. 
 Modular scaffolds made from PEG microspheres have been created as previously 
described (Nichols, Scott et al. 2009; Scott, Nichols et al. 2010).  Three types of microspheres 
were used to create the scaffolds (Figure 2.1).  There were structural microspheres that provided 
support and cell adhesion, microspheres that delivered S1P, and porogenic microspheres that 
contained hydrolyzable ester bonds.  Unreacted reactive groups on the surface of the 
microspheres were further crosslinked with BSA to fabricate the scaffolds (Figure 2.1).  These 
modular microsphere scaffolds that were shown to be porous and capable of supporting 
endothelial cell infiltration (Scott, Nichols et al. 2010) were implanted into mice to assess their in 
vivo vascularization. 
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Figure 2.1.  PEG scaffold formation.  Three sets of microspheres with different properties were 
assembled together to form bioactive modular scaffolds.  S1P loaded microspheres, structural 
microspheres with RGD peptide, and porogenic microspheres were centrifuged together in 2% 
BSA for 10 min at 1000 x g to form modular scaffolds.  The porogenic microspheres dissolved 
within two days to leave a crosslinked porous modular scaffold. 
 
2.3 Materials and Methods 
2.3.1 PEG8-Vinyl Sulfone Synthesis 
Unless otherwise stated, all reagents were purchased from Sigma-Aldrich.  The synthesis 
procedure was adapted from a procedure as previously described (Morpurgo, Veronese et al. 
1996; Scott, Nichols et al. 2008).  Eight-arm PEG-mesylate (PEG8-mesylate; mol wt 10,000) was 
first synthesized from eight-arm PEG-OH (PEG8-OH; mol wt 10,000; Creative PEGWorks) by 
mesylating the alcohol group on PEG8-OH with mesyl chloride.  This was done by dissolving 
PEG8-OH in toluene at 10% (w/v), drying the solution by azeotropic distillation, and cooling the 
solution to room temperature.  Dichloromethane (DCM) was added to 20% (v/v) before putting 
the solution on ice.  Four equivalents of triethylamine and four equivalents of methanesulfonyl 
chloride were added while on ice, and the reaction continued overnight under constant stirring 
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and nitrogen flow.  After removing the salt byproduct, excess DCM was removed by using the 
rotovap, and the PEG8-mesylate was precipitated out using cold diethyl ether.  The product was 
dried under vacuum overnight to remove any remaining diethyl ether.  The PEG8-mesylate was 
then converted to PEG8-hydroxyethyl sulfide.  To do this, the PEG8-mesylate was dissolved in 
deionized water at 10% (w/v) and four equivalents of 1M sodium hydroxide (NaOH) and four 
equivalents of β-mercaptoethanol were added.  The reaction was then performed at reflux for 
three hours.  Then the product was cooled on ice and extracted twice with DCM over anhydrous 
sodium sulfate (Na2SO4).  After removing the salt byproduct, excess DCM was removed by 
using the rotovap, and the PEG8-hydroxyethyl sulfide was precipitated out using cold diethyl 
ether.  The product was dried under vacuum overnight to remove any remaining diethyl ether.  
The PEG8-hydroxyethyl sulfide was then dissolved in 0.123 M sodium tungstate in distilled 
water at 25% (w/v).  Two equivalents of 30% hydrogen peroxide were added to the solution 
while on ice, and the reaction continued overnight under constant stirring and nitrogen flow.  
Then the product was extracted twice with DCM over anhydrous Na2SO4.  After removing the 
salt byproduct, excess DCM was removed by using the rotovap, and the PEG8-hydroxyethyl 
sulfone was precipitated out using cold diethyl ether.  The product was dried under vacuum 
overnight to remove any remaining diethyl ether.  The PEG8-hydroxyethyl sulfone was then 
dissolved in toluene at 10% (w/v), dried through azeotropic distillation, and cooled to room 
temperature.  DCM was added to 20% (v/v) before putting the solution on ice.  Three equivalents 
of triethylamine and 1.5 equivalents of methanesulfonyl chloride were added while on ice, and 
the reaction continued overnight under constant stirring and nitrogen flow.  Another three 
equivalents of triethylamine and 1.5 equivalents of methanesulfonyl chloride were added while 
on ice, and the reaction continued again overnight under constant stirring and nitrogen flow.  
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After removing the salt byproduct, excess DCM was removed by using the rotovap, and the 
PEG8-vinyl sulfone was precipitated out using cold diethyl ether.  The product was dried under 
vacuum overnight to remove any remaining diethyl ether.  Again the product was extracted twice 
with DCM over anhydrous Na2SO4.  After removing the salt byproduct, excess DCM was 
removed by using the rotovap, and the PEG8-vinyl sulfone was precipitated out using cold 
diethyl ether.  The product was dried under vacuum overnight to remove any remaining diethyl 
ether.  1H NMR (300 MHz, CDCl3, δ): 3.6 (PEG backbone), 6.35 (d, 2H, =CH2), 6.8 (m, 1H, -
SO2CH-).  NMR of the product confirmed vinyl sulfone features at 6.35 ppm and 6.8 ppm. 
 
2.3.2 PEG8-Amine Synthesis 
The synthesis procedure was adapted from a procedure as previously described (Elbert 
and Hubbell 2001).  PEG8-mesylate was synthesized as described earlier.  Eight-arm PEG-amine 
(PEG8-amine; mol wt 10,000) was then synthesized from PEG8-mesylate by an amination 
reaction with ammonium hydroxide.   PEG8-mesylate was first dissolved it in 400 mL of 28-30% 
ammonium hydroxide.  The PEG8-mesylate was constantly stirred in a sealed bottle for 3-4 days.  
Afterwards, the bottle was uncapped to allow the ammonia to evaporate while still under 
constant stirring for 3-5 days.  To collect the product, the pH of the solution was raised to 13 
with 1 M NaOH, and then extracted with DCM over anhydrous Na2SO4.  A standard DCM 
extraction procedure was done to extract the PEG8-amine into the DCM.  After three extractions, 
the Na2SO4 was filtered out and the combined DCM phase was rotovapped, diethyl ether 
precipitated, and dried as was done for the PEG8-mesylate.  1H NMR (300 MHz, CDCl3, δ): 3.6 
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(PEG backbone), 2.9 (t, 16H, -CH2-).  NMR of the product confirmed an amine end group by the 
presence of a triplet at 2.9 ppm. 
 
2.3.3 PEG8-Acrylate Synthesis 
The synthesis procedure was adapted from a procedure as previously described (Elbert 
and Hubbell 2001).  Eight-arm PEG-acrylate (PEG8-acrylate; mol wt 10,000) was synthesized 
from PEG8-OH.  This was done by dissolving PEG8-OH in toluene at 10% (w/v), drying the 
solution by azeotropic distillation, and cooling the solution to room temperature.  DCM was 
added to 20% (v/v) before putting the solution on ice.  1.5 equivalents of triethylamine and 1.5 
equivalents of acryloyl chloride were added while on ice, and the reaction continued overnight 
under constant stirring and nitrogen flow.  After removing the salt byproduct, excess DCM was 
removed by using the rotovap, and the PEG8-acrylate was precipitated out using cold diethyl 
ether.  The product was dried under vacuum overnight to remove any remaining diethyl ether.  
The product was then dissolved in deionized water at 10% (w/v) and sodium chloride was added 
until the solution reached 5% (w/v).  The pH was adjusted to pH 6 with NaOH, and the product 
was extracted three times with DCM over anhydrous Na2SO4.  After removing the any excess 
salts and byproducts, excess DCM was removed by using the rotovap, and the PEG8-acrylate was 
precipitated out using cold diethyl ether.  The product was dried under vacuum overnight to 
remove any remaining diethyl ether.  1H NMR (300 MHz, CDCl3, δ): 3.6 (PEG backbone), 4.3 (t, 
16H, -CH2-COO-), 5.8 (dd, 8H, -COO-CH2=CH).  NMR of the product confirmed an acrylate 
end group by the presence of a triplet at 4.3 ppm and a doublet of doublets at 5.8 ppm. 
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2.3.4 Microgel Formation and Characterization with Dynamic Light 
Scattering 
The synthesis procedure was adapted from a procedure as previously described (Scott, 
Nichols et al. 2008; Scott, Nichols et al. 2010).  Solutions of PEG8-vinyl sulfone, PEG8-amine, 
PEG8-acyrlate and bovine serum albumin (BSA) were prepared at 20% (w/v) in phosphate 
buffered saline (PBS; Pierce; pH 7.4) and sterile filtered with 0.22 µm syringe tip filters 
(Millipore).  Microgel solutions were formed to overcome the slightly higher reactivity of amines 
with vinyl sulfones than acrylates (Friedman, Cavins et al. 1965; Scott, Nichols et al. 2010).  
Through Michael-type conjugate addition reactions, PEG8-vinyl sulfone/BSA and PEG8-vinyl 
sulfone/PEG8-amine microgel solutions were formed by mixing PEG8-vinyl sulfone with either 
BSA or PEG8-amine solutions at ratios of 1:1 of vinyl sulfone to amine groups.  It was assumed 
that 8 moles of accessible functional groups per mole of PEG8-vinyl sulfone or PEG8-amine were 
available, and approximately 36 lysines were sterically accessible for reaction on BSA (Wacker, 
Scott et al. 2006).  PEG8-amine/PEG8-acrylate microgel solutions were formed by mixing the 
PEG8-amine and PEG8-acrylate solutions at ratios of 1:1 of amine to acrylate groups.  The 
microgel solutions were rotated at 40 RPM at 37°C until the mean effective hydrodynamic 
diameters (dPCS) reached an average of 100 nm as determined by dynamic light scattering/photon 
correlation spectroscopy (DLS/PCS; 90Plus Particle Size Analyzer, Brookhaven Instruments, 
Holtsville, NY).  The measurement was performed at a scattering angle of 90° and wavelength of 
658 nm.  Brookhaven Instruments Particle Sizing Software (version 2.34, Brookhaven 
Instruments) was used to calculate the dPCS and generate statistical analysis of the results. 
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2.3.5 Microsphere Fabrication 
The fabrication process was adapted from a procedure as previously described (Scott, 
Nichols et al. 2008; Scott, Nichols et al. 2010).  The microgel solution of PEG8-vinyl 
sulfone/PEG8-amine was diluted to 2% (w/v) at room temperature with PBS and 1.5 M Na2SO4 
in PBS to reach a final Na2SO4 concentration of 0.6M and volume of 250 µL.  The microgel 
solution of PEG8-vinyl sulfone/BSA was diluted to 2% (w/v) at room temperature with PBS and 
1.5 M Na2SO4 in PBS to reach a final Na2SO4 concentration of 0.65M and volume of 250 µL.  
The microgel solution of PEG8-amine/PEG8-acrylate was diluted to 2% (w/v) at room 
temperature with PBS and 1.5 M Na2SO4 in PBS to reach a final Na2SO4 concentration of 0.45M 
and volume of 250 µL.  Unless otherwise noted, the concentration of Na2SO4 was chosen to 
lower the LCST of PEG such that the PEG phase separated above room temperature but below 
the reaction temperature.  The solutions were then heated above the cloud point at 37°C for  
PEG8-vinyl sulfone/BSA and PEG8-vinyl sulfone/PEG8-amine, and the solutions were heated 
above the cloud point at 95°C for PEG8-amine/PEG8-acrylate.  Unless otherwise noted, the 
reaction was performed long enough such that the microspheres formed but aggregation was kept 
to a minimum.  To remove the Na2SO4, the microspheres were then buffer exchanged into PBS 
by diluting them 3:1 with PBS, titurating, and centrifuging at 14,100 x g for 2 minutes.   This 
process was repeated two more times. 
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2.3.6 S1P and RGD Incorporation into Microsphere Fabrication 
This process was adapted from a procedure as previously described (Scott, Nichols et al. 
2008; Scott, Nichols et al. 2010).  To deliver S1P (BIOMOL International), dried S1P was added 
to 20% (w/v) BSA in PBS at 1 nmol S1P/mg BSA and rotated at 37°C until S1P was solubilized.  
This solution was then added to PEG8-vinyl sulfone to form microgel solutions as previously 
described.  The PEG8-vinyl sulfone/BSA/S1P microgels were then used to form microspheres in 
the same manner as previously described for PEG8-vinyl sulfone/BSA microspheres. 
The addition of the cell adhesion peptide was done by mixing the pre-reacted solution of 
PEG8-vinyl sulfone/PEG8-amine (2:1 vinyl sulfone:amine, dPCS ≈ 50 nm, 20% (w/v) PEG) with 
RGD peptide (Seq: GCGYGRGDSPG; GenScript USA Inc.) at an RGD concentration of 5.5 
mM for 30 min at 37°C.  This formed PEG8-vinyl sulfone/PEG8-amine/RGD microgels.  The 
PEG8-vinyl sulfone/PEG8-amine/RGD microgels were then used to form microspheres in the 
same manner as previously described for PEG8-vinyl sulfone/PEG8-amine. 
 
2.3.7 Scaffold Formation for Implantation 
Two sets of scaffolds were made for implantation.  The control set comprised of PEG8-
vinyl sulfone/PEG8-amine/RGD microspheres, PEG8-vinyl sulfone/BSA microspheres, and 
PEG8-amine/PEG8-acrylate microspheres in a ratio of 1:1:1.  Scaffolds delivering S1P contained 
a mixture of PEG8-vinyl sulfone/PEG8-amine/RGD microspheres, PEG8-vinyl sulfone/BSA/S1P 
microspheres, and PEG8-amine/PEG8-acrylate microspheres in a ratio of 1:1:1.  The implantation 
scheme was a modification of a method developed by Chen et al. (Chen, Aledia et al. 2009).  For 
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each scaffold type, the microspheres were mixed together with 2% (w/v) BSA in PBS and placed 
in polydimethylsiloxane (PDMS; Dow Corning) chambers that had a height of 8 mm, an inner 
diameter of 8 mm, and an outer diameter of 10 mm.  These chambers simplified scaffold 
implantation and limited the infiltration of blood vessels to one side of the scaffold.  The 
microspheres were centrifuged at 1000 x g for 10 min in the PDMS chambers.  Excess BSA and 
PBS were removed and the PDMS chambers were trimmed until they were level with the 
scaffold.  
 
2.3.8 Scaffold Implantation and Explantation in Mice 
 Outbred mice (Hsd:ICR; Harlan) were used for the scaffold experiments.  The mice were 
anesthetized, shaved, and cleaned prior to surgery.  A 1.5 cm incision along the middle section of 
the mouse’s back was made.  Following the incision, subcutaneous pockets were formed 
underneath the skin with iris scissors at the left flank and right flank of the mouse.  Scaffolds 
without S1P were placed in the left flank, and scaffolds with S1P were placed in the right flank 
of the mouse.  PDMS chambers were oriented upright with scaffolds facing the skin.  The 
incision was then sutured up with Vicryl (Ethicon) suture and sealed with VetBond (3M).  After 
14 days, the mice were sacrificed, and the scaffolds were removed and fixed in 3.7% (w/v) 
formaldehyde solution for at least 24 hours. 
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2.3.9 Photoacoustic Microscopy 
Optical-resolution photoacoustic microscopy was performed on the fixed samples 
according to a procedure that has been previously reported (Geng, Xueding et al. 2004; Xu and 
Wang 2006; Rao, Li et al. 2010).  In general, nonionizing waves directed at the scaffold sample 
were used to excite wideband ultrasound waves that can be detected by ultrasonic transducers to 
form images (Xu and Wang 2006; Rao, Li et al. 2010).  Photoacoustic microscopy revealed any 
blood vessels that may have entered or have been recruited toward the scaffold. 
 
2.3.10 Hematoxylin and Eosin (H&E) Staining and Sectioning 
 Fixed scaffolds were sent to the AMP Core Lab at Washington University School of 
Medicine’s Department of Pathology & Immunology for H&E staining and sectioning.  Samples 
were then taken to the Hope Center at Washington University School of Medicine where images 
were captured using a NanoZoomer (Hamamatsu). 
 
2.4 Results and Discussion 
2.4.1 Microsphere and Scaffold Formation 
 Following the procedure that was previously demonstrated to successfully form 
microspheres from the reaction of PEG derivatives (Scott, Nichols et al. 2008; Scott, Nichols et 
al. 2010), we were able to form PEG8-vinyl sulfone/PEG8-amine/RGD, PEG8-amine/PEG8-
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acrylate, PEG8-vinyl sulfone/BSA/S1P, and PEG8-vinyl sulfone/BSA microspheres.  PEG8-vinyl 
sulfone/PEG8-amine/RGD microspheres served as structural microspheres and provided 
adhesion peptides for the cells.  PEG8-amine/PEG8-acrylate microspheres added porosity to the 
scaffolds.  These porogenic microspheres degraded after two days once their bonds were 
hydrolyzed.  PEG8-vinyl sulfone/BSA/S1P microspheres also served as structural microspheres 
and as a vehicle for delivery of S1P.  A set of scaffolds that served as the control group was 
created by suspending PEG8-vinyl sulfone/PEG8-amine/RGD, PEG8-amine/PEG8-acrylate, and 
PEG8-vinyl sulfone/BSA microspheres in 2% BSA in PBS and centrifuging them together at 
1000 x g for 10 min.  The scaffolds that delivered S1P were made by suspending PEG8-vinyl 
sulfone/PEG8-amine/RGD, PEG8-amine/PEG8-acrylate, and PEG8-vinyl sulfone/BSA/S1P 
microspheres in with 2% BSA in PBS and centrifuging them together at 1000 x g for 10 min.  It 
had been previously demonstrated that microspheres needed to be crosslinked in 2% fetal bovine 
serum (FBS) to form adequate scaffolds because the serum proteins served to crosslink the 
microspheres through the reaction of the amines on the proteins with the vinyl sulfone groups on 
the microspheres (Scott, Nichols et al. 2008; Scott, Nichols et al. 2010).  We replaced 2% FBS 
with 2% BSA in order to reduce the immunological response from the mice.  The microspheres 
successfully crosslinked with 2% BSA to form scaffolds similar to ones that crosslinked with 2% 
FBS.  The scaffolds were formed in PDMS chambers, so that they would be ready for 
implantation following fabrication. 
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2.4.2 Implantation of Scaffolds into Mice 
 After the scaffolds had been formed, they were subcutaneously implanted into mice.  The 
procedure for implanting the scaffolds is illustrated in Figure 2.2.  The controls without S1P 
were placed subcutaneously on the left flank of the mice, and the scaffolds delivering S1P were 
placed subcutaneously on the right flank of the mice.  The scaffolds were placed in PDMS 
chambers to simplify the implantation process, limit the infiltration of blood vessels to one side 
of the scaffold, preserve the structural integrity of the scaffold, and simplify explantation of the 
scaffold.  Scaffolds placed within the mice without PDMS chambers tend to shift back and forth 
as the mice move around, which can damage the scaffolds and complicate their explantation.  
The scaffolds were explanted after 14 days and remained intact. 
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Figure 2.2.  Schematic of scaffold and illustration of implantation procedure.  Once the scaffolds 
have been prepared, the mice were cleaned and an incision was made on their backs.  
Subcutaneous pockets were formed underneath the skin and scaffolds delivering S1P were 
placed on the right flank while control scaffolds were placed on the left flank of the mice.  The 
incision was closed following the procedure and the mice were monitored for 14 days until the 
scaffolds were explanted. 
 
2.4.3 Scaffold Explantation and Analysis 
 After 14 days, the scaffolds in their PDMS chambers were explanted from the mice, fixed 
in 3.7% formaldehyde solution for 24 hours, and analyzed by H&E staining or photoacoustic 
microscopy.  Prior to fixing the scaffolds, macroscopic images of the scaffold implants were 
taken to demonstrate the extent of vascular ingrowth into the scaffolds (Figure 2.3).  Vascular 
ingrowth into scaffolds was observed for both the control scaffolds and scaffolds delivering S1P, 
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but there was observably more ingrowth in scaffolds with S1P.  Half of the samples were 
prepared for photoacoustic microscopy, and the other half were prepared for H&E staining and 
sectioning.  The samples prepared for optical-resolution photoacoustic microscopy were excited 
with nonionizing waves in order to excite wideband ultrasound waves that were then detected by 
ultrasonic transducers to form images (Geng, Xueding et al. 2004; Xu and Wang 2006; Rao, Li 
et al. 2010).  Photoacoustic microscopy revealed that scaffolds with S1P recruited more blood 
vessels than those without S1P (Figure 2.4).  Images taken of scaffolds after H&E staining and 
sectioning also indicated that scaffolds delivering S1P had a higher prevalence of vascularization 
than those without S1P (Figure 2.5 and Figure 2.6).  Both techniques revealed qualitatively 
higher recruitment of blood vessels into the scaffolds that delivered S1P than the control 
scaffolds. 
 
Figure 2.3.  Pictures of scaffold implants.  The scaffold on the left released S1P while scaffold 
on the right had no S1P.  There is an observable difference in vascularization between the two 
scaffolds.  More blood vessels can be seen in the scaffold that delivered S1P. 
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Figure 2.4.  Photoacoustic microscopy images of scaffold implants.  The scaffold on the left 
released S1P while scaffold on the right had no S1P.  There is a qualitative increase in blood 
vessels being recruited to the scaffold delivering S1P than the scaffold without S1P. 
 
Scaffold Scaffold 
 33 
 
 
 
Figure 2.5.  Histology image of PEG scaffold without S1P after implantation.  The scaffold 
elicited an immunological response from the mouse that can be seen by the cells stained in blue 
bordering the scaffold.  Parts of the scaffold also suffered retraction or degradation. 
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Figure 2.6.  Histology image of PEG scaffold with S1P after implantation.  The scaffold elicited 
an immunological response from the mouse that can be seen by the cells stained in blue 
bordering the scaffold.  Parts of the scaffold also suffered retraction or degradation.  This 
scaffold also has areas marked with blood vessels and their supporting network of fibroblasts that 
the control scaffold lacked. 
 
The H&E images also revealed a large amount of foreign body response from the mice to 
both types of scaffolds.  This is indicated by the cells stained in blue that either surrounded or 
infiltrated the scaffolds (Figure 2.5 and Figure 2.6).  The images also show parts of the scaffolds 
experienced possible retraction or degradation that was likely due to the foreign body response.  
The use of BSA to form the microspheres and scaffolds was the likely cause of the 
immunological response from the mice.  Foreign body response and inflammation has been 
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shown to occur with implants (Anderson 1988), and more importantly inflammation has been 
demonstrated to induce angiogenesis (Imhof and Aurrand-Lions 2006; Granger and Senchenkova 
2010).  This explains the vascularization observed with both types of scaffolds.  While 
angiogenesis is welcomed, inflammation can lead to destruction or diseases of the surrounding 
tissue (Imhof and Aurrand-Lions 2006).  Ideally, the BSA would be removed in order to 
minimize the immunological response, but removing BSA will prevent forming some of the 
structural microspheres required to make the scaffolds.  Furthermore, BSA provided an effective 
means of highly crosslinking the microspheres and forming scaffolds that were strong enough to 
be implanted into mice.  A new system would be needed to reduce the immunological response 
and create scaffolds strong enough for implantation. 
 
2.5 Conclusions 
 We demonstrated that microsphere-based PEG scaffolds could be successfully implanted 
in mice and deliver S1P for the promotion of vascularization.  Prior to this work, microsphere-
based PEG scaffolds were shown to be highly biocompatible with endothelial cells, and they 
were shown to successfully introduce bioactivity in the form of RGD peptide conjugation and 
S1P delivery in vitro (Nichols, Scott et al. 2009; Scott, Nichols et al. 2010).  These promising in 
vitro studies of the scaffolds had mixed in vivo results.  Scaffolds delivering S1P recruited more 
blood vessels than those without any S1P delivery.  However, H&E staining revealed a 
significant amount of foreign body response to the scaffolds.  The BSA used to fabricate the 
microspheres and scaffolds was the cause of the immunological response observed.  Since BSA 
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has a pivotal role in fabricating the microspheres and scaffolds, a different approach will be 
required to have micropshere-based PEG scaffolds that do not invoke a large foreign body 
response.  We anticipate that the modular nature of these microsphere-based PEG scaffolds will 
present a solution that builds upon the groundwork of this study.    
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Chapter 31 
Clickable Poly(ethylene glycol) Microsphere-
Based Cell Scaffolds 
 
3.1 Abstract 
 Clickable poly(ethylene glycol) (PEG) derivatives are used with two sequential aqueous 
two-phase systems to produce microsphere-based scaffolds for cell encapsulation.  In the first 
step, sodium sulfate causes phase separation of the clickable PEG precursors and is followed by 
rapid gelation to form microspheres in the absence of organic solvent or surfactant.  The 
microspheres are washed and then deswollen in dextran solutions in the presence of cells, 
producing tightly packed scaffolds that can be easily handled while also maintaining porosity.  
Endothelial cells included during microsphere scaffold formation show high viability.  The 
clickable PEG microsphere-based cell scaffolds open up new avenues for manipulating scaffold 
architecture as compared to simple bulk hydrogels. 
 
 
 
                                                          
 
1 Chapter 3 has been adapted from the following manuscript:  
Nguyen PK, Snyder CG, Shields JD, Smith AW, Elbert DL. Clickable Poly(ethylene glycol)-
Microsphere-Based Cell Scaffolds. Macrolmol Chem Phys. 2013 Apr 25;214(8):948-956. 
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3.2 Introduction 
 Polymeric materials are promising as scaffolds for tissue reconstruction and drug delivery 
systems for the therapeutic release of bioactive molecules (Langer, Vacanti et al. 1995; Griffith 
2000; Hoffman 2002).  Poly(ethylene glycol) (PEG) is a widely used hydrophilic polymer that 
resists non-specific biological interactions (Lee, Lee et al. 1995; Peppas, Keys et al. 1999; 
Alcantar, Aydil et al. 2000), yet is readily modified with proteins and peptides for enzymatic 
biodegradation and cell adhesion (West and Hubbell 1999; Lutolf and Hubbell 2005; Zhu 2010).  
While PEG hydrogels have been demonstrated to be useful in a number of applications, modular 
or self-assembling hydrogel-based scaffolds promise to facilitate the generation of complex 
architectures that better mimic the organization of natural tissues (Lutolf and Hubbell 2005; 
Elbert 2011).  PEG scaffolds and hydrogels have been crosslinked using a wide variety of 
chemical reactions including free radical polymerization (Sawhney, Pathak et al. 1993), Michael-
type addition (Huang, Michel et al. 2001), enzymatic reaction (Sperinde and Griffith 1997), 
irradiation of linear or branched PEG polymers (Bray and Merrill 1973), mixed-mode 
polymerizations (Lee, Dalsin et al. 2002; Salinas and Anseth 2008), native chemical ligation 
(Hu, Su et al. 2009), and other strategies (Peppas, Keys et al. 1999; Zhu 2010).  Click reactions 
are defined as bioorthogonal reactions and include reactions such as the Huisgen 1,3 dipolar 
cycloaddition between azides and alkynes, thiol-ene/yne photoadditions, and Staudinger ligation 
(ten Brummelhuis, Diehl et al. 2008; Iha, Wooley et al. 2009; Nwe and Brechbiel 2009; Hoyle, 
Lowe et al. 2010; Park, Kloxin et al. 2010).  Taking advantage of the rapid reaction kinetics of 
copper(I)-catalyzed azide-alkyne cycloaddition, crosslinked hydrogel networks have been 
produced and tailored for various applications (Malkoch, Vestberg et al. 2006; Ossipov and 
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Hilborn 2006; Crescenzi, Cornelio et al. 2007; Polizzotti, Fairbanks et al. 2008; Liu, Ee et al. 
2009; Meng, Hendrickson et al. 2009; van Dijk, van Nostrum et al. 2010; Hu, Li et al. 2011).  
Crosslinked polymer networks have also been fabricated and modified for several applications 
using thiol-ene/yne photoadditions (Polizzotti, Fairbanks et al. 2008; Fairbanks, Scott et al. 2009; 
Impellitteri, Toepke et al. 2012).  Copper-free azide-alkyne cycloadditions have recently 
attracted attention for materials fabrication, as these reactions have high conversions, fast 
kinetics, insensitivity to oxygen and water, stereospecificity, regiospecificity, and mild reaction 
conditions (Johnson, Baskin et al. 2008; Clark and Kiser 2009; DeForest, Polizzotti et al. 2009; 
DeForest, Sims et al. 2010).  Additionally, the reactions can be performed under physiological 
conditions with little risk of non-specific reactions with molecules found in cells and tissues 
(Nwe and Brechbiel 2009).  Copper-free cycloadditions have been designed to allow 
incorporation of protease-sensitive peptides to enable enzymatic biodegradation (DeForest, 
Polizzotti et al. 2009; Fairbanks, Schwartz et al. 2009; DeForest, Sims et al. 2010; van Dijk, van 
Nostrum et al. 2010) and attachment of cell adhesion peptides through photoaddition (Polizzotti, 
Fairbanks et al. 2008; DeForest, Polizzotti et al. 2009; Fairbanks, Schwartz et al. 2009; DeForest, 
Sims et al. 2010).  Due to the exceedingly slow reaction kinetics of alkynes with thiols, amines, 
alcohols, etc., PEG scaffolds formed using click reactions may be useful for cell transplantation 
and drug delivery. 
We previously developed techniques for the fabrication of PEG microspheres by phase 
inversion polymerization (Nichols, Scott et al. 2009; Scott, Nichols et al. 2010; Elbert 2011).  By 
lowering the lower critical solution temperature (LCST) of PEG with kosmotropic salts, reactive 
PEG derivatives underwent a thermally induced phase separation.  Spherical PEG-rich domains 
coalesced and rapidly increased in size due to the absence of surfactants or stirring.  However, 
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coalescence was halted when the spherical domains reached the gel point (Nichols, Scott et al. 
2009).  We previously found that the mean size of the microspheres could be controlled quite 
precisely by altering the kinetics of the reaction, such that the gel point was reached at different 
times following phase separation (Nichols, Scott et al. 2009).  We sought to demonstrate the 
phase inversion polymerization technique could be adapted to azide-alkyne cycloadditions. 
 
3.3 Materials and Methods 
3.3.1 PEG4-Azide Synthesis 
 Unless otherwise stated, all reagents were purchased from Sigma-Aldrich.  Four-arm 
PEG-mesylate (PEG4-mesylate; mol wt 10,000) was first synthesized from four-arm PEG-OH 
(PEG4-OH; mol wt 10,000; Creative PEGWorks) by mesylating the alcohol group on PEG4-OH 
with mesyl chloride.  This was done by dissolving PEG4-OH in toluene at 10% (w/v), drying the 
solution by azeotropic distillation, and cooling the solution to room temperature.  
Dichloromethane (DCM) was added at 20% (v/v) before putting the solution on ice.  Four 
equivalents of triethylamine and four equivalents of methanesulfonyl chloride were added while 
on ice, and the reaction continued overnight under constant stirring and nitrogen flow.  After 
removing the salt byproduct, excess DCM was removed by using the rotovap, and the PEG4-
mesylate was precipitated out using cold diethyl ether.  The product was dried under vacuum 
overnight to remove any remaining diethyl ether.  The next step was the nucleophilic azidation of 
the mesylate group with sodium azide.  Three equivalents of sodium azide were dissolved in 
dimethylformamide (DMF).  PEG4-mesylate was then dissolved in the DMF mixture at 10% 
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(w/v) and put under nitrogen and constant stirring in a hot water bath at 60°C.  The reaction was 
run overnight.  The following day required the filtration of excess salt followed by rotovapping, 
diethyl ether precipitation, and drying as was done for the PEG4-mesylate.  The product was 
dissolved in a basic water solution with a pH between 9 and 12, and then extracted with DCM 
over anhydrous sodium sulfate (Na2SO4).  A standard extraction procedure was done to extract 
the product into DCM.  After three extractions, the Na2SO4 was filtered out and the process of 
rotovapping, diethyl ether precipitation, and drying was done as before.  1H NMR (300 MHz, 
CDCl3, δ): 3.6 (PEG backbone), 3.0 (s, 3H, -SO2CH3), 4.3 (t, 2H, -CH2OSO2-).   NMR of the 
product confirmed that no mesylate features remained at 3.0 ppm and 4.3 ppm (Figure 3.1). 
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Figure 3.1.  NMR of PEG4-azide.  PEG4-azide was synthesized using a two-step process.  The 
PEG backbone is located at 3.6 ppm.  The conversion of mesylate to azide is shown by the 
absence of signals at 3.0 ppm and 4.3 ppm. 
 
3.3.2 PEG4-Alkyne Synthesis 
PEG4-mesylate was synthesized as described earlier.  Four-arm PEG-amine (PEG4-
amine; mol wt 10,000) was then synthesized from PEG4-mesylate by an amination reaction with 
ammonium hydroxide.   PEG4-mesylate was first dissolved it in 400 mL of 28-30% ammonium 
hydroxide.  The PEG4-mesylate needed to be constantly stirred in a sealed bottle for 3-4 days.  
 43 
 
 
Afterwards, the bottle was uncapped to allow the ammonia to evaporate while still under 
constant stirring, which took 3-5 days.  To collect the product, the pH of the solution was raised 
to 13 with sodium hydroxide, and then extracted with DCM over anhydrous Na2SO4.  A standard 
DCM extraction procedure was done to extract the PEG4-amine into the DCM.  After three 
extractions, the Na2SO4 was filtered out and the combined DCM phase was rotovapped, diethyl 
ether precipitated, and dried as was done for the PEG4-mesylate.  The final step was PEG4-
alkyne synthesis from PEG4-amine.  PEG4-amine was dissolved in DCM in a beaker, and 1.5 
equivalents of diisopropylcarbodiimide (DIPCDI) was added to a separate spherical flask with 
DCM while on ice and under nitrogen flow and constant stirring.  Next, 1.5 equivalents of 
hydroxybenzotriazole (HOBt) and 1.5 equivalents of propiolic acid were added to the mixture in 
the flask and allowed to stir for 10 minutes.  While waiting, three equivalents of N,N-
diisopropylethylamine (DIPEA) were added to the dissolved PEG4-amine.  Finally, this mixture 
was slowly added to the spherical flask, and the reaction was allowed to go for 24 hours in the 
ice bath, under constant stirring and nitrogen gas.  Following that process, the urea precipitate 
was filtered out, and rotovapping, diethyl ether precipitation, and drying were performed.  The 
product was then dissolved in deionized water and underwent the same extraction procedure that 
was done for the PEG4-amine.  Further rotovapping, diethyl ether precipitation, and drying were 
done.  1H NMR (300 MHz, CDCl3, δ): 3.6 (PEG backbone), 2.1 (t, H, ≡CH).  NMR of the 
product confirmed the synthesis of PEG4-alkyne with the presence of a peak at 2.1 ppm (Figure 
3.2). 
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Figure 3.2.  NMR of PEG4-alkyne.  PEG4-azide was synthesized using a three-step process.  The 
PEG backbone is located at 3.6 ppm.  The conversion of amines to alkynes is shown by the 
signal at 2.1 ppm. 
 
3.3.3 PEG4-Cyclooctyne Synthesis 
The four-arm PEG-cyclooctyne (PEG4-cyclooctyne) synthesis was identical to the PEG4-
alkyne synthesis with the only difference being the use of an aza-dibenzocyclooctyne with a 
pendant carboxylic acid (DBCO-acid; Click Chemistry Tools) instead of propiolic acid.  1H 
NMR (300 MHz, CDCl3, δ): 3.6 (PEG backbone), 5.1 (d, 2H, -CH2-).  NMR of the product 
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confirmed the synthesis of PEG4-cyclooctyne with the presence of a doublet at 5.1 ppm (Figure 
3.3). 
 
Figure 3.3.  NMR of PEG4-cyclooctyne.  PEG4-cyclooctyne was synthesized using a three-step 
process.  The PEG backbone is located at 3.6 ppm.  The conversion of amines to cyclooctynes is 
shown by the signal at 5.1 ppm. 
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3.3.4 Preparation of Stock Solutions of PEG4-Azide, PEG4-Alkyne, PEG4-
Cyclooctyne, and PEG-Dithiol 
All PEG derivatives were synthesized as described earlier with the exception of linear 
PEG-thiol (PEG-dithiol; mol wt 3400; Creative PEGWorks).  Stock solutions of each PEG 
derivative were prepared at 20% (w/v) in phosphate buffered saline (PBS; Pierce; pH 7.4). 
 
3.3.5 PEG4-Azide/PEG4-Alkyne Hydrogel Synthesis 
PEG4-azide/PEG4-alkyne hydrogels were formed at room temperature or 37°C by 
combining stock solutions of PEG4-azide and PEG4- alkyne in a ratio of 1:1 with PBS, five 
equivalents of sodium L-ascorbate and 0.5 equivalents copper sulfate (Cu(II)SO4).  Equivalents 
were based on moles of azide.  After at least 2 minutes, 0.1 M ethylenediaminetetraacetic acid 
(EDTA) in PBS was added to the sample to chelate the copper.  Excess copper was removed by 
washing two more times with 0.1 M EDTA and three times with PBS.  The final PEG percentage 
was 10% (w/v). 
 
3.3.6 PEG4-Azide/PEG4-Cyclooctyne Hydrogel Synthesis 
PEG4-azide/PEG4-cyclooctyne hydrogels were formed at room temperature or 37°C  by 
combining stock solutions of PEG4-azide and PEG4-cyclooctyne in a ratio of 1:1with PBS.  The 
final PEG percentage was 10% (w/v). 
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3.3.7 PEG4-Azide/PEG4-Alkyne Microsphere Fabrication 
Stock solutions of PEG4-azide and PEG4-alkyne were combined with PBS, Na2SO4, 
sodium L-ascorbate, and Cu(II)SO4.  The final solution was in PBS and Na2SO4 with five 
equivalents of sodium L-ascorbate and 0.5 equivalents Cu(II)SO4 (equivalents based on moles of 
azide).  Unless otherwise noted, the concentration of Na2SO4 was chosen to lower the LCST of 
PEG such that the PEG phase separated above room temperature but below the reaction 
temperature.  The final PEG percentage was 2% (w/v) for the reaction with the two PEG 
derivatives combined in a ratio of 1:1.  Cu(II)SO4 was added last to avoid premature 
crosslinking.  Unless otherwise noted, the reaction was performed long enough such that the 
microspheres formed but aggregation was kept to a minimum.  To halt the reaction, EDTA in 
PBS was added to the sample to chelate the copper.  The microspheres were then centrifuged at 
14,100 x g for 2 minutes and excess supernatant was removed.   Na2SO4 and excess copper were 
removed by repeating this process two more times with 0.1 M EDTA and three times with PBS.     
 
3.3.8 PEG4-Azide/PEG4-Alkyne Scaffold Formation 
Scaffolds were formed from the washed PEG4-azide/PEG4-alkyne microspheres 
crosslinked with PEG-dithiol.  Scaffold formation was performed by combining stock solutions 
of PEG-dithiol with the washed microspheres in a ratio of 1 vol PEG-dithiol per 1 vol of 
microspheres, and then 30% (w/v) dextran (Mr ~100,000) in PBS was added to phase separate 
the PEG in the microspheres with 2 vol of dextran solution per 1 vol of microspheres/PEG-
dithiol.  The dextran/PEG microsphere solution was centrifuged at 1,000 x g for 10 minutes.  The 
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thiol-yne photoaddition reaction was initiated with visible light from a Xenon arc lamp 
(Genzyme Focal Seal LS 1000; filtered at 480-520 nm) with 10 mM Eosin Y in PBS as the 
photoinitiator.  The light was illuminated on the sample for at least 4 minutes. 
 
3.3.9 RGD Peptide Attachment to PEG4-Cyclooctyne 
This was accomplished by reacting a cysteine-containing RGD sequence (Seq: 
GCGYGRGDSPG; GenScript USA Inc.) with the cyclooctyne group on PEG with a thiol-yne 
photoaddition reaction.  RGD was added to the PEG4-cyclooctyne in a ratio of 1:8 RGD to 
cyclooctyne.  A PEG solution was prepared with PEG4-cyclooctyne, RGD, and 10 mM Eosin Y 
at 20% (w/v) in PBS.  The process was initiated with visible light from a Xenon arc lamp with 
Eosin Y acting as the photoinitiator and was performed for at least 4 minutes.  A stock solution 
of PEG4-cyclooctyne with RGD was then used for microsphere and scaffold fabrication. 
 
3.3.10 Michael-Type Addition of Thiols to Cyclococtyne Assay 
PEG4-cyclooctyne was tested to determine if a Michael-type addition might occur 
between the aza-dibenzocyclooctyne and thiols.  Stock solutions of PEG4-cyclooctyne and PEG-
dithiol were combined in a ratio of two thiols per cyclooctyne.  Solutions were left overnight on 
a 37°C heating block.  Samples were checked the next day for bulk hydrogel formation. 
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3.3.11 PEG4-Azide/PEG4-Cyclooctyne Microsphere Fabrication 
Stock solutions of PEG4-azide and PEG4-cyclooctyne (or PEG4-cyclooctyne with RGD) 
were combined with PBS and Na2SO4.  Unless otherwise noted, the concentration of Na2SO4 was 
chosen to lower the LCST of PEG such that the PEG phase separated above room temperature 
but below the reaction temperature.  The final PEG percentage was 2% (w/v) for the reaction 
with the two PEG derivatives combined at a ratio of 1:1.  One of the PEG derivatives was added 
last in the microsphere fabrication procedure to avoid premature crosslinking.  Unless otherwise 
noted, the reaction was performed long enough such that the microspheres formed but 
aggregation was kept to a minimum.  At the end of the reaction, three PBS washes as previously 
described for the PEG4-azide/PEG4-alkyne microsphere fabrication were performed to remove 
the Na2SO4.  The microspheres were then used immediately or diluted by 15 times their volume 
with PBS to slow down their reaction kinetics and stored at 4°C. 
 
3.3.12 PEG4-Azide/PEG4-Cyclooctyne Scaffold Formation 
Scaffolds were formed from the washed PEG4-azide/PEG4-cyclooctyne microspheres.  
Scaffold formation was performed by adding a 30% (w/v) dextran solution to phase separate the 
microspheres with 2 vol of dextran solution per 1 vol of microspheres.   The dextran/PEG 
microsphere solution was centrifuged at 1,000 x g for 10 minutes.  No crosslinker was required 
because residual azide and cyclooctyne groups at the surface of the microspheres reacted with 
each other to crosslink the microspheres. 
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3.3.13 Cell Attachment and Spreading Assay  
50 µL bulk gels were produced from a final concentration of 5% (w/v) PEG.  The 
solution consisted of 6.25 µL PEG4-azide stock solution, 6.25 µL PEG4-cyclooctyne stock 
solution with or without RGD, and 37.5 µL of PBS and was used to coat most of the area of a 22 
mm x 22 mm glass cover slip.  The solutions were spread to the edges of the cover slip in order 
to wrap the hydrogel around the cover slip and prevent them from coming off.  One set of cover 
slips had PEG with RGD, and another set of cover slips had PEG without RGD to serve as the 
control.  The cover slips were coated with PEG and allowed to sit for 5 minutes.  These glass 
cover slips were then placed in a 6-well plate, and 2 mL of endothelial growth media (EGM; 
MCDB 131 media supplemented with 10 µg/L epidermal growth factor, 10 mg/L heparin, 1.0 
mg/L hydrocortisone, 0.2% antibiotic-antimycin, 2% fetal bovine serum, and 12 mg/L bovine 
brain extract).  Each well was seeded with 1 x 105 human aortic endothelial cells (HAEC) 
(Alford, Wang et al. 2010), and images were taken after 48 h using an Olympus IX70 
microscope with an Olympus CPlanFl 10X/0.3 phase contrast objective. 
 
3.3.14 Fabrication of PEG4-Azide/PEG4-Cyclooctyne Microsphere-Based 
Scaffolds with RGD in the Presence of Cells 
Following the formation and washing of PEG4-azide/PEG4-cyclooctyne microspheres 
with RGD, the microspheres were centrifuged at 14,100 x g for 12 seconds to form a pellet and 
excess PBS was removed.  This was done three times to remove all excess PBS.  The 
microspheres were then resuspended in 200 µL of PBS with 500,000 HAEC.  The resuspended 
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microspheres and the HAEC were formed into scaffolds with the addition of 30% (w/v) dextran 
solution as described above for the PEG4-azide/PEG4-cyclooctyne scaffold formation procedure.  
Once the scaffolds were made, excess dextran and PBS are replaced with 3 mL of EGM. 
 
3.3.15 Fabrication of PEG4-Azide/PEG4-Cyclooctyne Bulk Hydrogels with 
RGD in the Presence of Cells  
PEG4-azide/PEG4-cyclooctyne hydrogels with RGD were formed by combining 100 µL 
PEG4-azide stock solution, 100 µL PEG4-cyclooctyne with RGD stock solution with 500,000 
HAEC resuspended in 200 µL of PBS.  Once the hydrogels were made, they were washed with 
PBS and supplemented with 3 mL of EGM. 
 
3.3.16 Cell Viability Assay for Scaffolds and Hydrogels 
A cell viability assay was performed on the scaffolds and hydrogels that were formed in 
the presence of HAEC.  A Live/Dead Viability/Cytotoxicity Kit (Invitrogen) was used to assess 
cell viability according to the manufacturer’s suggested protocol.  Scanning confocal microscopy 
was performed on the scaffolds and hydrogels with 10X (0.45 DIC L WD 4.0) and 2X (0.1 WD 
8.50) objectives using a Nikon Eclipse C1/80i scanning confocal microscope, and images were 
analyzed using EZ-C1 FreeViewer (Nikon Corporation).  Images taken with the 10X objective 
were processed in MATLAB to determine percent cell viability. 
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3.3.17 Scaffold Analysis with Fluorescent Labeling 
To image scaffolds that had been formed in the presence of cells, decellularization of the 
scaffolds was performed prior to labeling.  Cells were lysed using deionized water.  After 
inducing hypotonic shock for 30 minutes, the scaffolds were washed three times in PBS.  Alexa 
Fluor 488-azide (Invitrogen) was used to label the remaining cyclooctyne on the microspheres 
that formed the PEG scaffolds.  Labeling was done according to the manufacturer’s suggested 
protocol.  Scanning confocal microscopy was performed on the scaffolds with 10X and 2X 
objectives as described earlier.   
 
3.4 Results and Discussion 
3.4.1 Formation of Click Microspheres 
We investigated the formation of microspheres and porous scaffolds in the phase-
separated state using copper(I)-catalyzed and copper-free azide-alkyne cycloadditions.  For the 
copper(I)-catalyzed reaction, PEG4-azide was mixed with PEG4-alkyne, which was synthesized 
by the reaction of PEG4-amine with propiolic acid.  Reaction of PEG4-azide with PEG4-alkyne to 
form a bulk hydrogel at 37°C required the addition of Cu(II)SO4 and sodium L-ascorbate (Figure 
3.4a); however, some reaction was noted without copper at 95°C (results not shown).  For the 
copper-free reaction at 37°C, PEG4-azide was mixed with PEG4-cyclooctyne (Figure 3.4b).  The 
latter was synthesized by reaction of PEG4-amine with a commercially available carboxyl-
derivatized aza-dibenzocyclooctyne (Debets, van Berkel et al. 2010) (Figure 3.5).  In both the 
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copper(I)-catalyzed and copper-free reactions, each four-arm PEG derivative served as a 
potential crosslink site (functionality = 4), forming highly crosslinked hydrogel networks upon 
reaction (Figure 3.4c).   Reactive groups on the PEG monomers that are not consumed during 
microsphere formation should still be available for subsequent addition of biologically active 
molecules or further crosslinking (Scott, Nichols et al. 2010), which can be used for ‘bottom-up’ 
scaffold assembly (Figure 3.4c) (McGuigan and Sefton 2006; Fernandez and Khademhosseini 
2010; Elbert 2011). 
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Figure 3.4.  Clickable PEG microsphere formation.  Clickable PEG derivatives were reacted 
using either: (a) copper(I)-catalyzed, or (b) strain-promoted Huisgen 1,3 dipolar cycloaddition 
between azides and alkynes.  (c) In the presence of sodium sulfate, four-arm clickable PEG 
derivatives phase-separated and reacted to form highly crosslinked hydrogel microspheres.  
These microspheres contained residual reactive groups that allowed further crosslinking.  (d) 
Microspheres were formed using copper(I)-catalyzed azide-alkyne cycloaddition.  These 
microspheres were formed by inducing phase separation in 325 mM sodium sulfate upon heating 
to 37°C for 2 minutes.  (e) Microspheres were formed using strain-promoted azide-aza-
dibenzocyclooctyne cycloaddition.  These microspheres were formed by inducing phase 
separation in 250 mM sodium sulfate upon heating to 37°C for 2 minutes.  (f) and (g) Larger 
microspheres could be formed with the strain-promoted cycloaddition by inducing immediate 
phase separation at room temperature (25°C) with 500 mM sodium sulfate, mixing the solution 
by pipetting three times, and heating to 37°C for 2 minutes.  Mixing in the phase-separated state 
resulted in the formation of much larger microspheres due to enhanced coalescence of PEG-rich 
domains prior to gelation. 
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Figure 3.5.  The general mechanism behind the synthesis of clickable PEG derivatives.  (a) The 
synthesis of PEG4-azide involved the nucleophilic azidation of PEG4-mesylate with sodium 
azide.  (b) The synthesis of PEG4-alkyne involved the reaction of PEG4-amine and propiolic 
acid, following activation of the carboxylic acids by DIPCDI/HOBT.  (c) The synthesis of PEG4-
cyclooctyne was similar to the synthesis of PEG4-alkyne, but dibenzylcyclooctyne acid was 
substituted for propiolic acid. 
 
To produce microspheres, the clickable PEG derivatives were reacted in the phase-
separated state.  Small microspheres (1-10 microns) were generated in the presence of sodium 
sulfate for both the copper(I)-catalyzed reaction (Figure 3.4d) and the copper-free reaction 
(Figure 3.4e).  To form these small microspheres, the concentration of sodium sulfate was 
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chosen such that phase separation did not occur at room temperature, allowing mixing of the 
reagents prior to the thermally induced phase separation.  With the copper(I)-catalyzed reaction, 
325 mM sodium sulfate resulted in phase separation upon heating from room temperature to 
37°C.  A 2 minute reaction was sufficient for microsphere formation.  For the copper-free 
reaction, a concentration of 250 mM sodium sulfate was needed for the formation of small 
microspheres.  The lower concentration of sodium sulfate was required because the LCST of 
PEG was greatly depressed by the presence of the hydrophobic dibenzocyclooctyne on the PEG, 
which was similar to an effect previously observed with acrylates and vinyl sulfones on PEG 
(Nichols, Scott et al. 2009).  Microspheres could also be formed by substituting the sodium 
sulfate with dextran or polyacrylamide (mol wt 5 x 106-6 x 106; Polysciences, Inc.).  Both of 
these polymers form aqueous two-phase systems with PEG (Figure 3.6).  With PEG4-
cyclooctyne, much larger microspheres (e.g. diameters of 50 microns or greater) formed if higher 
sodium sulfate concentrations were used.  Higher sodium sulfate concentrations caused phase 
separation of the PEG derivatives at room temperature, and the mixing of the reagents resulted in 
the formation of larger droplets, presumably by flow-induced acceleration of coalescence (Figure 
3.4f and 3.4g).  The combination of large and small microspheres has been shown to produce 
stronger materials than those formed from particles of uniform size (Van Tomme, van Nostrum 
et al. 2008), and thus may be desirable and were further examined here. 
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Figure 3.6.  Microsphere fabrication conditions.  Microspheres could be formed using dextran or 
polyacrylamide instead of sodium sulfate to induce phase separation.  PEG4-azide/PEG4-alkyne 
microspheres made using 0.12 mg copper with: (a) 10% dextran in PBS and formed at 37°C for 
5 minutes, (b) 10% dextran in PBS and formed at 37°C for 10 minutes, (c) 2% polyacrylamide 
for 4 minutes at 70°C. 
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In contrast, the copper(I)-catalyzed reaction generally did not produce microspheres 
greater than 5 microns in diameter.  A high concentration of sodium sulfate (650 mM Na2SO4) 
produced only small microspheres with the copper(I)-catalyzed system (Figure 3.7).  Changes in 
the copper concentrations also did not affect microsphere size (Figure 3.8), nor did increases in 
the reaction temperature (Figure 3.9).  This is somewhat surprising as faster reaction kinetics 
should result in smaller microspheres (Nichols, Scott et al. 2009).  We have seen a similar result 
with photopolymerizations of PEG-diacrylate in which the presence of a precipitation 
polymerization was suggested to occur due to the enhanced solubility of the photoinitiator in the 
PEG-poor phase (Flake, Nguyen et al. 2011).  It is possible that the copper ions also prefer the 
PEG-poor phase, such that a precipitation polymerization occurs in this phase, and very little 
crosslinking occurs in the PEG-rich droplets.   
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Figure 3.7.  Varying reaction time for PEG4-azide/PEG4-alkyne microsphere fabrication.  PEG4-
azide/PEG4-alkyne microspheres made using 0.12 mg copper with 650 mM Na2SO4 in PBS 
mixed at 4°C and formed at 37°C.  (a) Microspheres reacted for 2 minutes.  (b) Microspheres 
reacted for 4 minutes.  The reaction time of the PEG played an important role because if the 
reaction time was too short, no microspheres would be recovered, and if the reaction time was 
too long, the microspheres would begin to aggregate. 
 
b) 
a) 
100 µm 
100 µm 
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Figure 3.8.  Varying copper concentration for PEG4-azide/PEG4-alkyne microsphere fabrication.  
PEG4-azide/PEG4-alkyne microspheres made using various concentrations of copper with 325 
mM sodium sulfate in PBS and formed at 37°C for 2 minutes.  (a) Microspheres fabricated with 
0.03 mg of copper.  (b) Microspheres fabricated with 0.06 mg copper.  (c) Microspheres 
fabricated 0.12 mg of copper.  Varying the copper concentration when forming microspheres in 
the presence of sodium sulfate appeared to have no effect on microsphere size.  This suggested a 
precipitation polymerization was occurring. 
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Figure 3.9.  Increasing reaction temperature for PEG4-azide/PEG4-alkyne microsphere 
fabrication.  PEG4-azide/PEG4-alkyne microspheres made using 0.12 mg copper with 5% 
dextran in PBS and formed at 70°C.  (a) Microspheres reacted for 3 minutes.  (b) Microspheres 
reacted for 2.5 minutes.   
 
3.4.2 Attachment of Cell Adhesion Peptides 
We envision using microsphere-based scaffolds for the transplantation of vascular 
endothelial cells to achieve rapid vascularization following transplantation (Rouwkema, Rivron 
et al. 2008; Chen, Aledia et al. 2009).  The high resistance of PEG materials to protein 
adsorption makes it necessary to functionalize the materials with cell adhesion peptides.  A 
cysteine-containing RGD peptide (Seq: GCGYGRGDSPG) was used in a photoactivated thiol-
yne reaction with PEG4-cyclooctyne (Figure 3.10a).  To determine the effectiveness of the RGD 
attachment protocol, a thin, non-porous bulk PEG hydrogel was formed from PEG4-azide and 
PEG4-cyclooctyne with about one RGD peptide per eight cyclooctyne groups.  Endothelial cells 
seeded on bulk hydrogels without RGD peptide were unable to spread (Figure 3.10b).  In 
contrast, endothelial cells seeded on hydrogels containing RGD peptide spread quite readily after 
24 hours (Figure 3.10c).  The success of attaching adhesion peptides indicates that other types of 
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peptides and molecules can be incorporated using photoactivated thiol-yne reaction for different 
functions, such as scaffold degradability. 
 
 
Figure 3.10.  Attachment of cell adhesion peptide by thiol-yne reaction.  (a) RGD peptide was 
added to PEG4-cyclooctyne via a thiol-yne photoaddition, reacting the thiol on a cysteine in the 
RGD peptide with aza-dibenzocyclooctyne on the PEG.   To demonstrate attachment of 
functional RGD peptide, HAEC were seeded on PEG4-azide/PEG4-cyclooctyne bulk hydrogels.  
(b) Without RGD, the HAEC were not able to spread after 24 hours.  (c) HAEC attached and 
spread on hydrogels containing RGD after 24 hours. 
 
 
Michael-type addition of thiols to some activated alkynes is known (Waykole and 
Paquette 1989).  To determine if a Michael-type addition might occur between the aza-
dibenzocyclooctyne and thiols, PEG4-cyclooctyne was incubated with PEG-dithiol in solution at 
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a PEG concentration of 20% (w/v).  This solution did not form a gel overnight at 37°C.  
However, a bulk gel formed within 4 minutes if Eosin Y was added to the solution and exposed 
to intense visible light (480-520 nm) (results not shown).  This indicated that the thiol-yne 
reaction occurred readily, but that the Michael-type addition was insignificant. 
 
3.4.3 Microsphere-Based Scaffold Formation 
PEG microspheres were formed and then clicked together to form porous scaffolds using 
reactions that should not harm living cells.  Due to the potential for copper toxicity (Baskin, 
Prescher et al. 2007), PEG4-azide/PEG4-alkyne microspheres were stitched together into a 
scaffold using a visible light-initiated thiol-yne reaction (Park, Kloxin et al. 2010) between PEG-
dithiol and residual alkyne groups in the microspheres (Figure 3.11).  This was further evidence 
of the specific nature of the thiol-yne reaction because microspheres formed with PEG4-azide 
and PEG4-alkyne and incubated with PEG-dithiol did not form scaffolds without photoinitiation 
(results not shown).  Scaffolds with better handling properties were then formed by reacting 
PEG4-azide/PEG4-cyclooctyne microspheres directly with each other.  We found that the 
crosslinking of the microspheres proceeded more efficiently in the phase-separated state (Smith, 
Segar et al. 2012), so a 500 µL mixture of microspheres and 500,000 HAEC was suspended on 
top of 500 µL of 30% (w/v) dextran (Figure 3.12a).  PEG/dextran aqueous two-phase systems 
are widely used for cellular partitioning (Albertsson 1986), and toxicity was not expected to be a 
concern based on previous results with a cardiomyocyte cell line (Smith, Segar et al. 2012).  
Phase separation caused the microspheres to deswell and rapidly crosslink around the cells 
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during centrifugation for 10 minutes at 1,000 x g.  Following centrifugation, excess dextran and 
PBS were replaced with endothelial growth medium. 
 
 
Figure 3.11.  PEG4-azide/PEG4-alkyne microsphere-based scaffold formation.  To form PEG4-
azide/PEG4-alkyne microsphere-based scaffolds, microspheres were suspended 1:1 (v/v) in 20% 
PEG-dithiol.  This mixture was then suspended 1:2 (v/v) in 30% dextran and centrifuged at 1,000 
x g for 10 minutes.  (a) Crosslinking of the microspheres was then performed with a thiol-yne 
photoaddition reaction. The process was initiated with visible light from a Xenon arc lamp (480-
520 nm) with 10 mM Eosin Y in PBS as the photoinitiator.  (b) Visible light was projected onto 
the microspheres at different angles for a total of 4 minutes to form a scaffold that was fragile but 
could be handled and manipulated with great care. 
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Figure 3.12.  Formation of scaffolds in the presence of cells.  (a) To form microsphere-based 
scaffolds, PEG microspheres were suspended 1:1 (v/v) in 30% dextran and centrifuged at 1,000 x 
g for 10 minutes.  In 30% dextran, the PEG in the microspheres phase-separated from the 
dextran, causing the microspheres to deswell.  This greatly enhanced reaction between the 
microspheres and resulted in stronger scaffolds.  The scaffold formed a layer consisting of 
microspheres mixed with cells on top of the diluted dextran phase following centrifugation.  
Cells were incorporated into the scaffolds simply by combining them with the PEG microspheres 
in 30% dextran just prior to scaffold formation.  (b) Once formed, PEG scaffolds supported their 
own weight and could be manipulated for routine cell culture.  (c) A Live/Dead assay 
demonstrated 87.8% ± 3.5% viability of HAEC 2 days after scaffold formation.  (d) Labeling of 
the microspheres with an azide-containing dye revealed a high degree of porosity within the 
scaffold. 
 
Structural stability, high cell viability, and a network of interconnected pores are required 
for the eventual vascularization of the scaffold (Yang, Leong et al. 2001; Karageorgiou and 
Kaplan 2005).  The formed scaffolds supported their own weight in solution and were able to be 
handled for cell culture and microscopy (Figure 3.12b).  Two days after scaffold formation, the 
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viability of the HAEC within the scaffolds was calculated to be 87.8% ± 3.5% (Figure 3.12c).  
The smaller images shown to the right and bottom of Figure 3.12c are stacks of cross-sections in 
the y-z plane and x-z plane, respectively.  These demonstrate that the cells are distributed in three 
dimensions within the scaffolds.  A control was performed with PEG4-azide/PEG4-cyclooctyne 
bulk hydrogels with RGD made in the presence of cells.  After 48 hours the calculated viability 
of the cells had dropped to 3.5% ± 0.8%.  Confocal images taken of the hydrogel support this 
data (Figure 3.13).  Comparatively, the microsphere-based scaffold performed much better than 
the standard bulk hydrogel.  This is believed to be a result of a superior porous network structure 
in the microsphere-based scaffolds. 
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Figure 3.13.  PEG4-azide/PEG4-cyclooctyne bulk hydrogel with RGD formed in the presence of 
cells 48 hours after fabrication.  A Live/Dead assay demonstrated 3.5% ± 0.8% viability of 
HAEC 2 days after scaffold formation (live cells = green, dead cells = red). 
 
To assess network pore structure, cells were removed from the scaffolds, and remaining 
cyclooctyne groups present in the scaffold were labeled with Alexa Fluor 488-azide dye.  Figure 
3.12d shows the high degree of porosity found in the scaffolds.  Microspheres in some regions of 
Figure 3.12d do not appear to be connected due to the two dimensional nature of scanning 
confocal microscopy.  The smaller images on the right and bottom of Figure 3.12d demonstrate 
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that the microspheres are in fact connected in three-dimensional space.  Figure 3.12d also 
qualitatively demonstrates the abundant availability of unreacted groups on the microspheres 
following microsphere and scaffold formation.  Unfortunately, due to the precise nature of 
fabricating microspheres, the density of the available unreacted groups on the microspheres 
cannot be readily adjusted without adversely affecting microsphere formation.  If the reaction 
time is decreased, then the quantity of microspheres will be reduced or no microspheres will 
form (Figure 3.7a).  If the reaction time between the PEG derivatives is extended, then the 
microspheres formed will undergo excessive aggregation, inhibiting scaffold formation later 
(Figure 3.7b).  Following the removal of the cells, the scaffolds could still be handled and 
manipulated without breaking, further illustrating the connectivity of the microspheres. 
 
3.5 Conclusions 
We demonstrated in this study that highly porous scaffold materials can be produced by 
manipulating azide-alkyne cycloadditions and phase separations.  The reactions were performed 
in two steps: one to produce hydrogel microspheres, and another to crosslink the microspheres 
with each other in the presence of cells.  The high viability of endothelial cells during the 
scaffold formation process suggests that these materials are promising candidates for in vivo 
vascularization strategies.  In contrast to bulk hydrogels, the cells are not technically 
encapsulated within the hydrogel, but rather are surrounded by a matrix of microspheres.  We 
anticipate that such a strategy will yield more tissue-like architectures than bulk hydrogels due to 
the highly porous nature of the materials.  
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Chapter 41 
Multifunctional Poly(ethylene glycol) 
Microspheres Used to Fabricate Modular 
Scaffolds for Vascularization 
 
4.1 Abstract 
The need for vascularization in tissue engineering has been an important challenge to 
overcome, since it is required to support cells in tissue-engineered constructs.  One strategy to 
vascularize cells has been to use growth factor delivering scaffolds.  The goal of this study was 
to produce scaffolds that promote vascularization via vascular endothelial growth factor (VEGF).  
Poly(ethylene glycol) (PEG) derivatives with multiple functional groups were used with two 
sequential aqueous two-phase systems to produce microsphere-based scaffolds for 
vascularization.  Synthesized with multiple functional groups, these PEG derivatives were then 
formed into microspheres through phase separation and rapid gelation without the use of organic 
solvents or surfactants.  These multifunctional microspheres, which contain clickable reactive 
groups, were then deswollen in dextran solutions and crosslinked together via their reactive click 
groups to form tightly packed porous scaffolds.  The scaffolds were loaded with VEGF and 
                                                          
 
1 Chapter 4 has been adapted from the following unpublished manuscript:  
Nguyen PK, Kinstlinger IS, Shirure VS, George SC, Elbert DL. Multifunctional poly(ethylene 
glycol) microspheres used to fabricate modular scaffolds for vascularization. Journal of 
Biomedical Materials Research Part A. (In submission). 
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delivered it without loss of bioactivity.  The scaffolds were also co-cultured with normal human 
lung fibroblasts (NHLFs) and endothelial colony-forming cell-derived endothelial cells (ECFC-
ECs) to demonstrate their vascularization capabilities.  After 21 days, the scaffolds demonstrated 
small regions of vascularization.  The vascularization in these scaffolds was comparable to what 
we had observed with similar scaffold implants in mice.  The multifunctional nature of the 
scaffolds enables integration of ideal features for vascularization, such as cell adhesion, 
controlled growth factor release, and adjustable mechanical properties.  The versatility of these 
scaffolds may prove to be pivotal in forming extensive vascular networks for biomedical 
applications. 
 
4.2 Introduction 
 The mechanisms of vascularization have been an important research endeavor, since 
numerous aspects of tissue engineering rely on supporting living cells and tissue.  Tissue-
engineered constructs that use or interact with living cells and tissues need to provide the means 
to carry out their biological functions.  Cells and tissues further than 200 µm away from blood 
vessels have limited access to oxygen and nutrients and are unable to adequately remove carbon 
dioxide and cellular waste products (Carmeliet and Jain 2000; Rouwkema, Rivron et al. 2008; 
Novosel, Kleinhans et al. 2011; Auger, Gibot et al. 2013).  Without a blood vessel network close 
enough to support cells and tissues, they are unable to function properly and eventually undergo 
cell death (Chu and Wang 2012; Auger, Gibot et al. 2013; Birbrair, Zhang et al. 2014).  This 
problem can be solved through neovascularization, which primarily occurs through 
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vasculogenesis and angiogenesis.  Vasculogenesis is the formation of new blood vessels without 
any preexisting vasculature, and angiogenesis is the formation of new blood vessels from 
preexisting vascularization (Auger, Gibot et al. 2013).  Natural and synthetic biomaterials, such 
as poly(ethylene) glycol (PEG), poly(lactic-co-glycolic acid), fibrin gels, collagen, and Matrigel, 
have been used in tissue engineering approaches to form three-dimensional scaffolds to address 
this need for vascularization (Kim, Baez et al. 2000; Levenberg, Rouwkema et al. 2005; 
McGuigan and Sefton 2006; Chen, Aledia et al. 2009; Montaño, Schiestl et al. 2009; Chen, He et 
al. 2010; Du, Ghodousi et al. 2011; Elbert 2011).  Synthetic biomaterials are especially 
promising because their properties can be easily modified for different tissue engineering 
applications. 
 PEG is an ideal synthetic biomaterial for an approach to vascularization of cells and 
tissues due to its many desirable properties.  PEG is a hydrophilic polymer that has been shown 
to resist protein adsorption and non-specific biological interactions (Lee, Lee et al. 1995; Peppas, 
Keys et al. 1999; Alcantar, Aydil et al. 2000; Donahoe, Cohen et al. 2013) and can be modified 
to provide useful biological functions, such as cell adhesion and enzymatic biodegradation (West 
and Hubbell 1999; Lutolf and Hubbell 2005; Zhu 2010).  PEG can also be modified to take 
advantage of a wide variety of chemical reactions including Michael-type addition and 
bioorthogonal click reactions (Huang, Michel et al. 2001; Agard, Prescher et al. 2004; Iha, 
Wooley et al. 2009).  More recently, the versatility of PEG has expanded with the introduction 
PEG derivatives with more than a single type of functional group per PEG molecule (Obermeier, 
Wurm et al. 2011).  While the properties of PEG have made it useful for bulk hydrogel and 
surface coating applications, one of the more strategic implementations of PEG for tissue 
engineering has been as modular or self-assembling hydrogel-based scaffolds with architecture 
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that better replicates the properties of natural tissues (Lutolf and Hubbell 2005; Scott, Nichols et 
al. 2010; Elbert 2011; Smith, Segar et al. 2012; Donahoe, Cohen et al. 2013; Nguyen, Snyder et 
al. 2013).  Modular PEG scaffolds are comprised of different components that can be tailored to 
suit different types of applications.  
 Previously, modular PEG scaffolds were fabricated with PEG microspheres that were 
formed by phase inversion polymerization (Scott, Nichols et al. 2010; Elbert 2011; Smith, Segar 
et al. 2012; Nguyen, Snyder et al. 2013).  The process was initiated by lowering the lower critical 
solution temperature (LCST) of reactive PEG derivatives with kosmotropic salts to induce 
thermal phase separation.  They formed PEG-rich domains that coalesced and increased in size 
until they reached the gel point.  The microspheres formed through this technique presented 
reactive groups on their surface that interacted with crosslinkers under favorable conditions to 
form modular PEG scaffolds.  In this study, we synthesize PEG derivatives with more than one 
type of functional group (multifunctional PEG) to create PEG microspheres and scaffolds using 
the same techniques, but without the need for extra crosslinkers.  The mechanical properties of 
these scaffolds were similar to those that were previously fabricated (Scott, Nichols et al. 2010; 
Smith, Segar et al. 2012), but with more adjustability.  In addition, growth factors can be 
delivered from these scaffolds without affecting their bioactivity.  We sought to demonstrate that 
these new types of scaffolds formed from multifunctional PEG could be used for vascularization 
applications.  
 
4.3 Materials and Methods 
Unless otherwise stated, all reagents were purchased from Sigma-Aldrich. 
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4.3.1 PEG8-Vinyl Sulfone Synthesis 
 The synthesis procedure of eight-arm PEG-vinyl sulfone (PEG8-vinyl sulfone) from 
eight-arm PEG-OH (PEG8-OH; mol wt 10,000; Creative PEGWorks) was adapted from a 
procedure as previously described (Morpurgo, Veronese et al. 1996; Scott, Nichols et al. 2008).  
Solutions of PEG8-vinyl sulfone were prepared at 20% (w/v) in phosphate buffered saline (PBS; 
Pierce; pH 7.4) and sterile filtered with 0.22 µm syringe tip filters (Millipore). 
 
4.3.2 PEG8-Amine Synthesis 
 The synthesis procedure of eight-arm PEG-amine (PEG8-amine) from eight-arm PEG-
mesylate (PEG8-mesylate) was adapted from a procedure as previously described (Elbert and 
Hubbell 2001; Scott, Nichols et al. 2008).  PEG8-mesylate was synthesized from PEG8-OH as 
described in the procedure for PEG8-vinyl sulfone synthesis (Morpurgo, Veronese et al. 1996; 
Scott, Nichols et al. 2008).  Solutions of PEG8-amine were prepared at 20% (w/v) in PBS and 
sterile filtered with 0.22 µm syringe tip filters. 
 
4.3.3 PEG8-Acrylate Synthesis 
The synthesis procedure of eight-arm PEG-acrylate (PEG8-acrylate) from PEG8-OH was 
adapted from a procedure as previously described (Elbert and Hubbell 2001; Scott, Nichols et al. 
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2008).  Solutions of PEG8-acrylate were prepared at 20% (w/v) in PBS and sterile filtered with 
0.22 µm syringe tip filters. 
 
4.3.4 PEG8-Azide/Amine Synthesis 
The synthesis procedure of eight-arm PEG-azide/amine (PEG8-azide/amine) was adapted 
from a procedure for eight-arm PEG-azide (PEG8-azide) synthesis as previously described 
(Nguyen, Snyder et al. 2013).  PEG8-azide was then partially reduced to PEG8-amine by 
reduction of the azide groups to amine groups via Staudinger Reduction.  The procedure was 
adapted from a previously described method (Wallace, Hanes et al. 2005).  PEG8-azide was 
dissolved in tetrahydrofuran (THF) and 1.15 equivalents of triphenylphosphine (Ph3P) and 30 
equivalents of ultrapure H2O were added while on ice, and the reaction was allowed to go 
overnight under constant stirring and nitrogen flow.  A large excess of H2O to Ph3P was needed 
for amine formation.  Only enough Ph3P and H2O were added to reduce approximately 50% of 
the azide groups to amine groups.  Excess THF and H2O were removed by rotovapping, and 
PEG8-azide/amine and triphenylphosphine oxide (TPPO) were precipitated out using cold diethyl 
ether.  The product and byproduct were dried under vacuum overnight to remove any remaining 
diethyl ether.  Once dry, the PEG8-azide/amine and TPPO have cold toluene added, since TPPO 
is soluble in cold toluene and PEG is insoluble.  The PEG8-azide/amine was then vacuum filtered 
to remove the TPPO.  The product then underwent the same extraction procedure with 
dichloromethane (DCM) that was done in the PEG8-azide synthesis.  1H NMR (300 MHz, 
CDCl3, δ): 3.6 (PEG backbone), 2.9 (t, 2H, -CH2CH2NH2).  NMR of the product confirmed the 
reduction of some azides to amines with the amine feature at 2.9 ppm (Figure 4.1).  Solutions of 
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PEG8-azide/amine were prepared at 20% (w/v) in PBS and sterile filtered with 0.22 µm syringe 
tip filters. 
 
Figure 4.1.  NMR of PEG8-azide/amine.  PEG8-azide/amine was synthesized using a three-step 
process.  The PEG backbone is located at 3.6 ppm.  The reduction of some azides to amines is 
shown by calculating the signal intensity for the amine peak at 2.9 ppm. 
 
4.3.5 PEG8-Cyclooctyne/Amine Synthesis 
The synthesis procedure of eight-arm PEG-cyclooctyne/amine (PEG8-cyclooctyne/amine) 
was adapted from a procedure for eight-arm PEG-cyclooctyne (PEG8-cyclooctyne) synthesis as 
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previously described (Nguyen, Snyder et al. 2013).  PEG8-amine was synthesized as described 
previously.  Then approximately half of the amines on PEG8-amine were converted to 
cyclooctynes.  PEG8-amine was dissolved in DCM in a beaker, and 0.5 equivalents of 
diisopropylcarbodiimide (DIPCDI) were added to a separate spherical flask with DCM while on 
ice and under nitrogen flow and constant stirring.  Next, 0.5 equivalents of hydroxybenzotriazole 
(HOBt) and 0.5 equivalents of aza-dibenzocyclooctyne with a pendant carboxylic acid (DBCO-
acid; Click Chemistry Tools) were added to the mixture in the flask and allowed to stir for 10 
minutes.  While waiting, one equivalent of N,N-diisopropylethylamine (DIPEA) was added to 
the dissolved PEG8-amine.  Finally, this mixture was slowly added to the spherical flask, and the 
reaction was allowed to go for 24 hours in the ice bath, under constant stirring and nitrogen gas.  
Following that process, the urea precipitate was filtered out, and rotovapping, diethyl ether 
precipitation, and drying were performed.  The product was then dissolved in distilled H2O and 
underwent the same extraction procedure that was done for the PEG8-amine.  Further 
rotovapping, diethyl ether precipitation, and drying were done.  1H NMR (300 MHz, CDCl3, δ): 
3.6 (PEG backbone), 5.4 (d, 2H, -CH2-), 2.9 (t, 16H, -CH2-NH2).  NMR of the product confirmed 
the conversion of some amines to cyclooctynes with the presence of a doublet at 5.4 ppm and the 
presence of amine groups with a triplet at 2.9 ppm (Figure 4.2).  Solutions of PEG8-
cyclooctyne/amine were prepared at 20% (w/v) in PBS and sterile filtered with 0.22 µm syringe 
tip filters. 
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Figure 4.2.  NMR of PEG8-cyclooctyne/amine.  PEG8-cyclooctyne/amine was synthesized using 
a three-step process.  The PEG backbone is located at 3.6 ppm.  The partial conversion of amines 
to cyclooctynes is shown by the signal at 5.4 ppm.  Some amines are still present shown by the 
signal at 2.9 ppm. 
 
4.3.6 PEG8-Azide/Amine/PEG8-Vinyl Sulfone Microsphere Fabrication 
The fabrication process of these structural microspheres was adapted from a procedure as 
previously described (Nguyen, Snyder et al. 2013).  The PEG8-azide/amine solution was 
combined with PEG8-vinyl sulfone in a ratio of 1:1 azide/amine groups to vinyl sulfone groups.  
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The PEG8-azide/amine/PEG8-vinyl sulfone solution was diluted to 2% (w/v) at room temperature 
with PBS and 1.5 M sodium sulfate (Na2SO4) in PBS to reach a final concentration of 0.45M and 
volume of 500 µL.  The concentration of Na2SO4 was chosen to lower the LCST of PEG such 
that the PEG phase separated above room temperature but below the reaction temperature.  The 
solutions were then heated above the cloud point at 70°C for 5 minutes.  To remove the Na2SO4, 
the microspheres were then buffer exchanged into PBS by diluting them 3:1 with PBS, titurating, 
and centrifuging at 14,100 x g for 2 minutes.   This process was repeated two more times. 
 
4.3.7 PEG8-Cyclooctyne/Amine/PEG8-Vinyl Sulfone Microsphere Fabrication     
 The fabrication process of these structural microspheres was adapted from a procedure as 
previously described (Nguyen, Snyder et al. 2013).  The PEG8-cyclooctyne/amine solution was 
combined with PEG8-vinyl sulfone in a ratio of 1:1 cyclooctyne/amine groups to vinyl sulfone 
groups.  The PEG8-cyclooctyne/amine/PEG8-vinyl sulfone solution was diluted to 2% (w/v) at 
room temperature with PBS and 1.5 M Na2SO4 in PBS to reach a final concentration of 0.45M 
and volume of 500 µL.  The concentration of Na2SO4 was chosen to lower the LCST of PEG 
such that the PEG phase separated above room temperature but below the reaction temperature.  
The solutions were then heated above the cloud point at 70°C for 5 minutes.  To remove the 
Na2SO4, the microspheres were then buffer exchanged into PBS by diluting them 3:1 with PBS, 
titurating, and centrifuging at 14,100 x g for 2 minutes.   This process was repeated two more 
times. 
 
 79 
 
 
4.3.8 Porogenic Microsphere Fabrication 
The fabrication process was adapted from a procedure as previously described (Nguyen, 
Snyder et al. 2013).  The PEG8-cyclooctyne/amine solution was combined with different ratios 
PEG8-vinyl sulfone and PEG8-acrylate to tailor the porosity of microsphere scaffolds.  
Microspheres were created with a ratio of 2:1:1 cyclooctyne/amine to vinyl sulfone to acrylate 
groups unless otherwise stated.  The PEG8-cyclooctyne/amine/PEG8-vinyl sulfone/PEG8-acrylate 
solution was diluted to 2% (w/v) at room temperature with PBS and 1.5 M Na2SO4 in PBS to 
reach a final concentration of 0.45M and volume of 500 µL.  The concentration of Na2SO4 was 
chosen to lower the LCST of PEG such that the PEG phase separated above room temperature 
but below the reaction temperature.  The solutions were then heated above the cloud point at 
70°C for 5 minutes.  To remove the Na2SO4, the microspheres were then buffer exchanged into 
PBS by diluting them 3:1 with PBS, titurating, and centrifuging at 14,100 x g for 2 minutes.   
This process was repeated two more times. 
 
4.3.9 Laminin Attachment to PEG Microspheres 
 The addition of cell adhesion peptide was done by mixing the PEG8-azide/amine/PEG8-
vinyl sulfone microspheres and the PEG8-cyclooctyne/amine/PEG8-vinyl sulfone microspheres 
with laminin (Life Technologies) at 40 µg/mL and incubated at 4°C overnight.  The cysteines on 
laminin react with available vinyl sulfone groups on the surface of the microspheres to 
covalently couple laminin to the microspheres.  Microspheres are then buffered exchanged into 
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PBS three times by diluting them 3:1 with PBS, titurating, and centrifuging at 14,100 x g for 2 
minutes. 
 
4.3.10 Cysteine Capping of Excess Vinyl Sulfones 
 After laminin functionality was added to the microspheres, the microspheres were capped 
with cysteines to prevent any unreacted vinyl sulfone groups from inadvertently reacting later.  
The microspheres were incubated with L-cysteine at 2.5 mg/mL for 30 minutes at room 
temperature.  Microspheres are then buffered exchanged into PBS three times by diluting them 
3:1 with PBS, titurating, and centrifuging at 14,100 x g for 2 minutes. 
 
4.3.11 PEG8-Azide/Amine/PEG8-Vinyl Sulfone/PEG8-
Cyclooctyne/Amine/PEG8-Vinyl Sulfone Scaffold Formation 
 The scaffold fabrication process was adapted from a procedure as previously described 
(Smith, Segar et al. 2012; Nguyen, Snyder et al. 2013).  Scaffolds were formed by combining 
PEG8-azide/amine/PEG8-vinyl sulfone microspheres and PEG8-cyclooctyne/amine/PEG8-vinyl 
sulfone microspheres in a ratio of 1:1 in the presence of 40% (w/v) dextran in PBS to phase 
separate the microspheres.  Twice the volume of microspheres was added as dextran.  The 
mixture was then centrifuged at 1,000 x g for 10 min. 
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4.3.12 PEG8-Azide/Amine/PEG8-Vinyl Sulfone/PEG8-
Cyclooctyne/Amine/PEG8-Vinyl Sulfone/PEG8-Acrylate Porous Scaffold 
Formation 
The scaffold fabrication process was adapted from a procedure as previously described 
(Smith, Segar et al. 2012; Nguyen, Snyder et al. 2013).  Scaffolds were formed by combining 
PEG8-azide/amine/PEG8-vinyl sulfone microspheres and PEG8-cyclooctyne/amine/PEG8-vinyl 
sulfone/PEG8-acrylate microspheres in a ratio of 1:1 in the presence of 40% (w/v) dextran in 
PBS to phase separate the microspheres.  Twice the volume of microspheres was added as 
dextran.  The mixture was then centrifuged at 1,000 x g for 10 min.  After two days hydrolysis of 
the ester bonds created a porous scaffold. 
 
4.3.13 Scaffold Formation in the Presence of Fibroblast and Endothelial cells 
 Scaffolds formed in the presence of cells are fabricated in the same manner as described 
earlier under PEG8-azide/amine/PEG8-vinyl sulfone/PEG8-cyclooctyne/amine/PEG8-vinyl 
sulfone/PEG8-acrylate scaffold formation.  However, prior to the centrifugation step, cells are 
added to the microspheres. 2.5 million cells per mL of cord blood endothelial colony-forming 
cell-derived endothelial cells (ECFC-ECs; University of California, Irvine Medical Center) and 5 
million cells per mL normal human lung fibroblasts (NHLFs; American Type Culture 
Collection) were added to the scaffolds for a total of 7.5 million cells per mL at a ratio of 2:1 
NHLF to ECFC-EC.  The mixture was then centrifuged at 200 x g for 10 min.  Scaffolds were 
then placed in endothelial growth medium (EGM-2; Lonza) with 2% fetal bovine serum (FBS).  
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Scaffolds were maintained at 37°C in 100% humidified air containing 5% CO2.  The media was 
changed every other day for 21 days. 
 
4.3.14 Fibrin-Based Tissue Constructs 
 Fibrin-based tissue constructs were fabricated using a variation of a previously described 
method (Chen, Aledia et al. 2009).  Polydimethylsiloxane (PDMS; Dow Corning) chambers 
were prepared by mixing together PDMS and curing agent in a tissue culture dish (Corning) in a 
ratio of 10:1 and cured overnight in a vacuum chamber.  Rings of PDMS with an inner diameter 
of 6 mm, an outer diameter of 8 mm, and a thickness of 1 mm were cut from the cured PDMS.  
The PDMS rings were then placed on 12 mm round glass cover slips (Ted Pella) to form the 
PDMS chambers.  The PDMS chambers were sterilized with UV light for one hour.  Next, 
fibrinogen was dissolved in Dulbecco’s phosphate-buffered saline (DPBS) at 10 mg/mL and 
sterile filtered with 0.22 µm syringe tip filters.  NHLFs and ECFC-ECs were added in a ratio of 
2:1 with the final cell concentration of 7.5 million cells per mL.  40 µL of the cell-fibrinogen 
mixture was added to each PDMS chamber and 2.4 µL of 50 U/mL thrombin was thoroughly 
mixed into the cell-fibrinogen mixture to form the fibrin-based tissue construct.  The tissue 
constructs were then placed in EGM-2.  Tissue constructs were maintained at 37°C in 100% 
humidified air containing 5% CO2.  The media was changed every other day for 21 days. 
 
 
 83 
 
 
4.3.15 VEGF Bioactivity Assay 
 The VEGF bioactivity assay was adapted from a previously described endothelial cell 
migration assay (Alford, Kaneda et al. 2009; Alford, Wang et al. 2010).  A monolayer of 
immortalized human aortic endothelial cells (HAEC-hT) (Alford, Wang et al. 2010) were 
cultured in 6-well tissue culture plates (Corning) with endothelial growth media (EGM; MCDB 
131 media supplemented with 10 µg/L epidermal growth factor, 10 mg/L heparin, 1.0 mg/L 
hydrocortisone, 0.2% antibiotic-antimycin, 2% fetal bovine serum, and 12 mg/L bovine brain 
extract).  Once the cells formed a monolayer, they were serum starved for 12 hours with low 
serum media (LSM; 0.1% fetal bovine serum and 1% antibiotic-antimycin).  Scrape wounds 
were made using a 1 mL pipette tip to scrape the plates in the shape of a cross.  Microspheres 
were loaded via diffusion with enough VEGF (Life Technologies) to deliver 10 ng/mL and then 
were crosslinked to form scaffolds.  VEGF loaded scaffolds and scaffold controls were placed in 
the wells.  Images were taken at day 0, 1, 2, and 3 using an Olympus IX70 microscope with an 
Olympus CPlanFl 10X/0.3 phase contrast objective.  Wound gap was measured and processed 
using ImageJ software (NIH).  
 
4.3.16 Heparin Attachment 
 Heparin attachment was adapted from a previously method (Roam, Nguyen et al. 2014).  
Heparin was incorporated into the scaffolds after the microsphere fabrication step.  A solution of 
500 mM N-(3-Dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC), 12.5 mM N-
Hydroxy-succinimide (NHS), and 5% (w/v) heparin sodium salt in MES buffer (10 mM, pH 6.0) 
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was incubated at room temperature for 30 min.  The activated heparin solution was added to the 
PEG8-azide/amine/PEG8-vinyl sulfone microspheres and PEG8-cyclooctyne/amine/PEG8-vinyl 
sulfone microspheres at an amine to heparin molar ratio of 20:1.  The microspheres were 
incubated with the activated heparin solution for 30 min at room temperature.  The microspheres 
were then buffer exchanged into PBS three times as previously described. 
 
4.3.17 Mechanical Analysis of Scaffolds  
 Analysis of scaffolds using oscillatory shear rheometry (RFS3, Rheometric Scientific) 
was adapted as previously described (Smith, Segar et al. 2012).  Standard scaffolds and porous 
scaffolds were fabricated as previously described.  The scaffolds were approximately 10 mm in 
diameter and 2 mm thick.  The scaffolds were characterized using 8 mm steel plates with the gap 
distance set to 1 mm to prevent slipping.  A strain sweep established the extent of the scaffolds’ 
linearity to confirm that measurements were in the linear viscoelastic region.  Frequency sweeps 
were then performed up and down the range of 0.1571 rads/s to 1.571 rads/s at 5% strain in order 
to obtain the storage modulus (G’). 
 
4.3.18 Immunofluorescent Staining 
 Immunofluorescent staining was performed from a variation of a previously described 
process (Chen, Aledia et al. 2009; Chen, Aledia et al. 2010; White, Hingorani et al. 2012; White, 
Pittman et al. 2014).  Scaffolds and fibrin-based tissue constructs were washed three times with 
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PBS and fixed in 10% formalin in PBS.  The samples were then blocked in 2% (w/v) bovine 
serum albumin (BSA) in PBS at 4°C for an hour.  The primary antibody, mouse anti-human 
CD31 (Abcam), was diluted 1:200 in 2% (w/v) BSA, and added to the samples for overnight 
incubation at 4°C.  Samples were then washed in 2% (w/v) BSA for 20 minutes four times.  The 
secondary antibody, Alexa Flour 488-labeled goat anti-mouse (Life Technologies), was diluted 
1:500 in 2% (w/v) BSA, and added to the samples for overnight incubation at 4°C.  Samples 
were then washed in 2% (w/v) BSA for 20 minutes four times.  DAPI (Life Technologies) was 
added at 5 µg/mL and incubated for 30 min at room temperature.  Finally, they were washed 
with 2% (w/v) BSA.  Samples were stored in 10% formalin at 4°C when not in use. 
 
4.3.19 Microscopy 
Scanning confocal microscopy that was performed on the scaffolds and fibrin-based 
tissue constructs using either a Nikon Eclipse C1/80i scanning confocal microscope or an 
Olympus FV1200 laser scanning confocal microscope.  Images from these microscopes were 
analyzed using EZ-C1 FreeViewer (Nikon Corporation) and FV10-ASW Viewer (Olympus 
Corporation), respectively.  Brightfield microscopy was performed for the bioactivity assay 
using an Olympus IX70 microscope, and images were analyzed with ImageJ. 
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4.3.20 Statistical Analysis 
 The results of quantification are reported as a mean ± standard deviation.  Statistical 
comparisons between conditions were performed using one-way ANOVA with a post hoc Tukey 
test.  Results were considered statistically significant if p < 0.05. 
 
4.4 Results and Discussion 
4.4.1 Multifunctional PEG Synthesis 
 We developed a method for synthesis of eight-arm PEG with two types of functional 
groups on a single PEG molecule.  This development of the synthesis of PEG8-azide/amine and 
PEG8-cyclooctyne/amine builds upon previous work from our laboratory (Nguyen, Snyder et al. 
2013).  Synthesis of PEG8-azide/amine required only one additional step after the PEG8-azide 
was produced.  PEG8-azide/amine was made by partially reducing the azide groups to amine 
groups via Staudinger reduction (Wallace, Hanes et al. 2005).  In order to obtain approximately 
an equal ratio of azide and amine groups, 1.15 equivalents of Ph3P and 30 equivalents of 
ultrapure H2O were needed for the reaction.  Several attempts were required to optimize the 
procedure and reach the final ratio, since the equivalents used in established methods are 
normally designed to react all available azide groups.  Calculation of the NMR peak of the 
amines at 2.9 ppm with regard to the PEG backbone at 3.6 ppm verified that the final product 
that was approximately 50% azide and 50% amine (Figure 4.1).  Synthesis of PEG8-
cyclooctyne/amine was simpler in that only required a modification of the step converting 
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amines into cyclooctynes.  In order to obtain approximately an equal ratio of cyclooctyne and 
amine groups, only 0.5 equivalents of DIPCDI, HOBt, DIPEA, and DBCO-acid were needed for 
the reaction.  The procedure went through several rounds of optimization in order to obtain a 
product that had approximately an equal number of cyclooctyne and amine groups.  Calculation 
of the NMR peak of the amines at 2.9 ppm and the cyclooctynes at 5.4 ppm with regard to the 
PEG backbone at 3.6 ppm confirmed the final product had approximately and equal ratio of 
cyclooctynes to amines (Figure 4.2). 
 
4.4.2 Microsphere and Scaffold Fabrication 
 Microsphere and scaffold fabrication was adapted from methods that had been previously 
developed (Scott, Nichols et al. 2008; Scott, Nichols et al. 2010; Nguyen, Snyder et al. 2013) and 
combined them in a new way to improve upon modular PEG scaffolds.  Previously, 
microspheres were fabricated by lowering the LCST of PEG with Na2SO4 to thermally induce 
phase separation and create spherical PEG-rich domains that coalesced until they reached the gel 
point and form microspheres (Scott, Nichols et al. 2008; Nichols, Scott et al. 2009; Scott, 
Nichols et al. 2010; Nguyen, Snyder et al. 2013).  This method was still used to create 
microspheres by combining PEG8-azide/amine with PEG8-vinyl sulfone or PEG8-
cyclooctyne/amine with PEG8-vinyl sulfone in 450 mM Na2SO4 at 70°C for 5 minutes.  These 
combinations created the structural microspheres PEG8-azide/amine/PEG8-vinyl sulfone and 
PEG8-cyclooctyne/amine/PEG8-vinyl sulfone (Figure 4.3).  Unreacted vinyl sulfones on the 
surface of the microspheres can be used to add desired functionalities to the microspheres.  The 
microspheres were capped with L-cysteine once all desired functionalities were added.  The 
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reactive click groups on the microspheres were used to form scaffolds from the microspheres via 
PEG/dextran aqueous two-phase system as described previously (Elbert 2011; Smith, Segar et al. 
2012; Nguyen, Snyder et al. 2013).  In dextran, microspheres deswelled and rapidly crosslinked 
during centrifugation at 1,000 x g for 10 minutes (Figure 4.4). 
 
Figure 4.3.  Fabrication of structural PEG microspheres.  PEG8-cyclooctyne/amine or PEG8-
azide/amine was combined with PEG8-vinyl sulfone in 450 mM Na2SO4 at 70°C for 5 minutes.  
Unreacted vinyl sulfones on the surface of the microspheres can be used to add desired 
functionalities to the microspheres prior to being capped with L-cysteine. 
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Figure 4.4.  Fabrication of PEG8-cyclooctyne/amine/PEG8-vinyl sulfone/PEG8-
azide/amine/PEG8-vinyl sulfone scaffolds.  (a) Macroscopic image of PEG scaffold.  (b) PEG8-
cyclooctyne/amine/PEG8-vinyl sulfone microspheres were mixed and centrifuged with PEG8-
azide/amine/PEG8-vinyl sulfone microspheres in 40% (w/v) dextran at 1,000 x g for 10 minutes.  
Phase separation caused microspheres to deswell and the click reactive groups crosslinked 
together to form stable scaffolds. 
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Porogenic microspheres could be created in the same fashion by combining PEG8-
azide/amine or PEG8-cyclooctyne/amine with PEG8-acrylate instead of PEG8-vinyl sulfone in 
450 mM Na2SO4 at 70°C for 5 minutes.  These combinations created the porogenic microspheres 
PEG8-azide/amine/PEG8-acrylate and PEG8-cyclooctyne/amine/PEG8-acrylate.  However, for the 
sake of simplicity we only created and used PEG8-cyclooctyne/amine/PEG8-acrylate porogenic 
microspheres (Figure 4.5).  The amount of porosity introduced into the scaffold can be tailored 
by the addition of PEG8-vinyl sulfone along with PEG8-acrylate.  The ratio of PEG8-vinyl 
sulfone to PEG8-acrylate controls the porosity. A higher ratio of PEG8-vinyl sulfone adds more 
structural stiffness while more PEG8-acrylate adds more porosity.  Combining PEG8-
cyclooctyne/amine, PEG8-acrylate, and PEG8-vinyl sulfone produced mainly PEG8-
cyclooctyne/amine/PEG8-vinyl sulfone/PEG8-acrylate microspheres with the possible formation 
of PEG8-cyclooctyne/amine/PEG8-acrylate microspheres and PEG8-cyclooctyne/amine/PEG8-
vinyl sulfone microspheres (Figure 4.6).  Vinyl sulfones were capped with L-cysteine after all 
desired functionalities were added.  The reactive click groups on the microspheres were used to 
form porous scaffolds from the combination of these microspheres with the structural 
microspheres via PEG/dextran aqueous two-phase system.  Microspheres deswelled in 40% 
(w/v) dextran and rapidly crosslinked during centrifugation at 1,000 x g for 10 minutes (Figure 
4.7).  Within 48 hours the porogenic microspheres dissolved leaving a porous scaffold.  These 
porous scaffolds are similar to ones previously created (Scott, Nichols et al. 2010), but they did 
not require the addition of serum proteins for crosslinking into scaffolds because of the added 
click functionality.  As a result, these scaffolds have increased biocompatibility to make them 
more suitable as implants for vascularization. 
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Figure 4.5.  Fabrication of porogenic PEG microspheres.  PEG8-cyclooctyne/amine was 
combined with PEG8-acrylate in 450 mM Na2SO4 at 70°C for 5 minutes.  These microspheres 
dissolved within two days if left in an aqueous environment. 
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Figure 4.6.  Tailoring of porogenic PEG microspheres for porous scaffold fabrication.  PEG8-
cyclooctyne/amine was combined with PEG8-acrylate and PEG8-vinyl sulfone at 450 mM 
Na2SO4 at 70°C for 5 minutes.  Adjusting the ratio of acrylates to vinyl sulfones increased or 
decreased the amount of porosity that was introduced into the scaffolds.  This process produced 
mainly microspheres with both acrylates and vinyl sulfones (PEG8-cyclooctyne/amine/PEG8-
vinyl sulfone/PEG8-acrylate microspheres) with the possible formation of structural 
microspheres (PEG8-cyclooctyne/amine/PEG8-acrylate microspheres) and porogenic 
microspheres (PEG8-cyclooctyne/amine/PEG8-vinyl sulfone microspheres). 
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Figure 4.7.  Fabrication porous scaffolds.  (a) Macroscopic image of porous PEG scaffold.  (b) 
PEG8-cyclooctyne/amine/PEG8-acrylate microspheres were mixed and centrifuged with PEG8-
azide/amine/PEG8-vinyl sulfone microspheres in 40% (w/v) dextran at 1,000 x g for 10 minutes.  
Phase separation caused microspheres to deswell, and the click reactive groups crosslinked 
together to form stable scaffolds.  Within 48 hours the porogenic microspheres dissolved leaving 
a porous scaffold.  Using porogenic microspheres found in Figure 4.6 yielded similar results. 
 
4.4.3 Scaffold Mechanical Properties 
 Scaffolds created by previous work (Scott, Nichols et al. 2008; Scott, Nichols et al. 2010) 
had storage moduli that were an order of magnitude lower than those of bulk PEG hydrogels, 
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making them delicate.  However, they held together if carefully handled and had storage moduli 
that were lower than heart tissue, similar to liver tissue, and higher than collagen gels or Matrigel 
(Raeber, Lutolf et al. 2005; Cullen, Lessing et al. 2007; Levental, Georges et al. 2007; Lai, Li et 
al. 2008; Jiao, Clifton et al. 2012).  The stiffness of these scaffolds was limited by their 
fabrication process until PEG/dextran aqueous two-phase system was implemented to fabricate 
the modular scaffolds (Elbert 2011; Smith, Segar et al. 2012; Nguyen, Snyder et al. 2013).  The 
scaffolds fabricated using this system could be made to match the storage moduli of heart tissue 
(Jiao, Clifton et al. 2012; Smith, Segar et al. 2012).  Scaffolds made from multifunctional PEG 
derivatives demonstrated a range of storage moduli.  Scaffolds consisting of only structural 
microspheres exhibited a storage moduli greater than scaffolds previously made (G’ = 700 – 
1,000 Pa) using the PEG/dextran aqueous two-phase system and closer to that of PEG hydrogels 
(Figure 4.8) (Scott, Nichols et al. 2010; Roberts, Earnshaw et al. 2011; Smith, Segar et al. 2012).  
Porous scaffolds formed with an equal amount of structural and porogenic microspheres had a 
storage modulus that was comparable to modular scaffolds created by crosslinking microspheres 
with serum proteins (G’ = 200 – 400 Pa) (Figure 4.9) (Scott, Nichols et al. 2010).  The rheometry 
data suggests that scaffolds can be tailored to varying degrees of stiffness within the range of G’ 
of approximately 400 to 1,400 Pa by adjusting the amount of porogenic microspheres 
incorporated into the scaffolds. 
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Figure 4.8.  Rheometry data of nonporous PEG microsphere scaffold.  PEG8-
cyclooctyne/amine/PEG8-vinyl sulfone/PEG8-azide/amine/PEG8-vinyl sulfone scaffolds had a 
storage moduli (G’) greater than scaffolds previously made with serum proteins or the 
PEG/dextran aqueous two-phase system. 
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Figure 4.9.  Rheometry data of porous PEG microsphere scaffold.  PEG8-
cyclooctyne/amine/PEG8-acrylate/PEG8-azide/amine/PEG8-vinyl sulfone scaffolds had a storage 
moduli (G’) comparable to scaffolds previously made with serum proteins. 
 
4.4.4 VEGF Delivery and Bioactivity 
 In order to achieve better vascularization in the modular PEG scaffolds, VEGF was 
loaded into the multifunctional PEG microspheres before being crosslinked into scaffolds and 
their bioactivity was tested after being released from the scaffolds.  PEG8-azide/amine/PEG8-
vinyl sulfone and PEG8-cyclooctyne/amine/PEG8-vinyl sulfone microspheres were loaded with 
VEGF and centrifuged in the presence of dextran to form scaffolds.  Enough VEGF was loaded 
to deliver 10 ng/mL of VEGF for the bioactivity assays.  HAEC-hTs were cultured in 6-well 
plates until they formed a monolayer.  The cells were serum starved in LSM for 12 hours before 
the scrape wound assay was performed.  Scaffolds delivering VEGF and scaffold controls were 
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placed in the wells with scrape wounds, and scrape wound distances were measured for four 
days.  Scaffolds that did not deliver VEGF did not display a significant change in wound width 
(ANOVA and a Tukey post-hoc test; Figure 4.10).  Scaffolds that were loaded with VEGF 
showed a significant change (p < 0.05) in wound width in next three days when compared to Day 
0 (Figure 4.11).  This suggests that VEGF remained active after being loaded and released from 
the scaffolds.  Thus, the bioactivity of VEGF was not affected by the microsphere and scaffold 
fabrication process. 
 
Figure 4.10.  Wound width of scaffolds without VEGF delivery.  The scrape wound assay 
revealed no significant changes in wound width from scaffolds without VEGF after three days. 
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Figure 4.11.  Wound width of scaffolds delivering VEGF.  The scrape wound assay revealed a 
significant difference (p < 0.05) in wound width when comparing days 1, 2, and 3 to day 0.  This 
indicated that the bioactivity of VEGF from these scaffolds was still present after being loaded 
and released. 
 
 We aimed to control the release of VEGF from the scaffolds by incorporating heparin 
into the microspheres.  We chose heparin to control the release of VEGF, since it has been 
shown to specifically bind a variety of proteins, such as growth factors, cytokines, and enzymes 
(Sasisekharan and Venkataraman 2000; Capila and Linhardt 2002; Knaack, Lode et al. 2014).  
More specifically, it has been shown that heparin controlled release of VEGF improved 
angiogenesis and blood vessel maturation (Steffens, Yao et al. 2004; Nillesen, Geutjes et al. 
2007; Chen, He et al. 2010; Knaack, Lode et al. 2014).  In order to incorporate heparin into the 
scaffolds, heparin was activated with EDC/NHS and reacted with the amines on the PEG8-
azide/amine/PEG8-vinyl sulfone and PEG8-cyclooctyne/amine/PEG8-vinyl sulfone microspheres 
(Figure 4.12).  The microspheres were loaded with VEGF as was described and crosslinked 
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together in dextran to form scaffolds.  The scrape wound assay was performed on these scaffolds 
to determine if heparin had an effect on VEGF delivery in these scaffolds.   The results from the 
assay depict a decreasing wound width trend, but the differences in wound widths were not 
found to be statistically significant (p > 0.05) (Figure 4.13).  Since previous results demonstrated 
that VEGF bioactivity was not affected by the scaffolds fabrication process and other studies 
have demonstrated functional controlled release of VEGF with heparin, we concluded that not 
enough VEGF was released to make a statistically significant difference in wound width.  
Heparin may have decreased the burst release of VEGF from the scaffolds, reducing the amount 
of delivered VEGF needed to promote endothelial cell migration.  The results indicate that the 
controlled release of VEGF in the heparinated scaffolds needs to be modified and measured in 
order to achieve a controlled burst release of VEGF that is needed to promote vascularization. 
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Figure 4.12.  Heparin attachment onto PEG microspheres.  Heparin was activated with 
EDC/NHS and added to the microspheres to react with the available amine groups.  The 
heparinated microspheres were then loaded with VEGF and centrifuged in the presence of 
dextran to form scaffolds. 
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Figure 4.13.  Wound width of heprinated scaffolds delivering VEGF.  The scrape wound assay 
revealed a trend in decreasing wound width when comparing days 1, 2, and 3 to day 0.  
However, the differences in wound width were not statistically significant (p > 0.05). 
 
4.4.5 Vascularization of PEG Scaffolds  
 Porous scaffolds were fabricated in the presence of cells to assess their ability to support 
vascularization.  The PEG/dextran aqueous two-phase system described earlier was used to form 
scaffolds in the presence of cells because they have been widely used for cellular partitioning 
and do not adversely affect cells (Albertsson 1986; Smith, Segar et al. 2012; Nguyen, Snyder et 
al. 2013).  NHLFs and ECFC-ECs were used to vascularize the scaffolds because they have been 
successfully used in fibrin-based tissue constructs and fibrin gels to create blood vessel networks 
(Chen, Aledia et al. 2009; Moya, Alonzo et al. 2014).  PEG8-azide/amine/PEG8-vinyl sulfone 
microspheres were chosen to provide the structural support needed for the scaffold.  To add 
porosity to the scaffold, porogenic PEG8-cyclooctyne/amine/PEG8-vinyl sulfone/PEG8-acrylate 
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microspheres were fabricated with a ratio of 1:1 vinyl sulfone to acrylate.  This ratio was chosen 
to make the scaffold porous but not too delicate to handle.  Cell adhesion peptide was added by 
mixing the microspheres with laminin and incubating overnight.  Laminins are proteins in the 
extracellular matrix, and they make up part of the basement membrane.  Laminin contains the 
peptide sequence RGD in its alpha-chain that promotes adhesion of endothelial and fibroblast 
cells (Couchman, Höök et al. 1983; Beck, Hunter et al. 1990).  Following laminin attachment 
and capping of excess vinyl sulfone groups, the microspheres were buffer exchanged, and 
NHLFs and ECFC-ECs were added to the microspheres.  The mixture of cells and microspheres 
was combined with dextran and centrifuged to form cell-based PEG scaffolds.  Within two days, 
the porogenic microspheres dissolved to increase scaffold porosity.  Scaffolds were cultured for 
21 days before they were analyzed.  Fibrin-based tissue-engineered constructs were also made 
concurrently with the scaffolds to serve as a positive control.  Fibrin gels with NHLFs and 
ECFC-ECs were formed in PDMS chambers to create the fibrin-based tissue-engineered 
constructs.  They were cultured for 21 days, after which both the scaffolds and fibrin-based 
tissue-engineered constructs were fixed and immunofluorescently stained to assess 
vascularization with confocal microscopy.  Both the fibrin-based tissue constructs and the PEG 
scaffolds had vascularization after 21 days (Figure 4.14).  The fibrin-based tissue constructs had 
extensive vascularization while the porous scaffolds were limited to small regions of 
vascularization.  The vascularization of the fibrin-based tissue constructs was expected, since 
NHLFs and ECFC-ECs have been shown to migrate through fibrin gels and form vascular 
networks (Brown, Lanir et al. 1993; Lafleur, Handsley et al. 2002; Chen, Aledia et al. 2009; 
Moya, Alonzo et al. 2014).  Since the porous PEG scaffolds can be extensively modified, the 
vascularization results proved to be very promising for the potential of these scaffolds for 
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vascularization.  Making adjustments to the porosity of the scaffolds and incorporating 
biodegradability into these scaffolds are just a few of the modifications that can be made to 
improve vascularization within the scaffold.  We anticipate that several strategies can be used to 
improve the PEG scaffolds to have them match the vascularization found in fibrin-based tissue 
constructs. 
 
 104 
 
 
 
Figure 4.14.  Immunofluorescent images of fibrin-based tissue constructs and porous PEG 
scaffolds with lamin after co-culturing NHLFs and ECFC-ECs for 21 days (ECFC-ECs = green, 
nuclei = blue).  (a) Vascularization was prominent in the fibrin gels after 21 days.  (b) Vessel 
formation was found in the porous PEG scaffolds in a few small regions after 21 days. 
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4.5 Conclusions 
In this study we demonstrated the fabrication of microspheres from multifunctional PEG 
derivatives and crosslinked them together to form porous modular PEG scaffolds for 
vascularization.  The multifunctional nature of the PEG derivatives allowed for simple 
modification with additional functionalities, such as cell adhesion and VEGF delivery, while 
maintaining biocompatibility.  The scaffolds were fabricated to exhibit a range of mechanical 
stiffness by changing the composition of the porogenic and structural microspheres.  They could 
also be loaded with VEGF and deliver the growth factor without losing bioactivity.  Finally, co-
culturing fibroblasts and endothelial cells in the porous PEG scaffolds demonstrated that they 
could provide a potential environment for vascularization.  We anticipate that the addition of 
more functionality, such as degradability, to the porous PEG scaffolds can improve their ability 
to support vascularization. 
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Chapter 5 
Conclusions 
5.1 Summary of Dissertation 
 An ongoing challenge in tissue engineering has been to develop ways of supporting cells 
and tissues in tissue-engineered constructs and scaffolds.  Vascularization has been studied as a 
solution to this problem by directing blood flow to cells and tissues.  The goal of this work was 
to fabricate porous scaffolds that delivered growth factors and directed angiogenesis into the 
scaffolds.  In Chapter 2, we created porous modular PEG microsphere-based scaffolds for in vivo 
vascularization.  Reactive PEG derivatives were synthesized, and microspheres were made by 
exploiting the LCST of PEG.  Microspheres were made to create pores, provide structural 
support, provide cell adhesion, and deliver S1P.  These microspheres were crosslinked together 
with BSA to form scaffolds and were implanted in mice.  We removed them after 14 days to 
assess how well the scaffolds induced angiogenesis.  Photoacoustic microscopy revealed that 
scaffolds delivering S1P demonstrated greater recruitment of blood vessels than control 
scaffolds.  This was confirmed with H&E staining of scaffold sections.  However, the H&E 
staining also revealed that the scaffolds caused foreign body response.  This was mainly 
attributed to the BSA used to control the delivery of S1P and crosslink the microspheres into 
scaffolds.  Since BSA was needed to fabricate the scaffolds, we devised a new way to crosslink 
PEG microspheres into scaffolds.   
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In Chapter 3, we synthesized new PEG derivatives with click functionalities because of 
their bioorthogonal properties.  Click reactions are highly specific reactions that do not have 
unwanted interactions with other proteins and biomolecules.  We also replaced BSA with a 
PEG/dextran aqueous two-phase system to crosslink the microspheres into scaffolds.  
Microspheres and scaffolds were initially made with copper catalyzed click reactions and thiol-
yne photopolymerizations.  However, the copper catalyst was toxic to cells, so we used strain-
promoted click reactions.  This change removed any potential toxicity and simplified the 
fabrication of the microspheres and scaffolds, since we could now make them without a copper 
catalyst and photopolymerizable crosslinker molecule.  RGD peptide was incorporated into the 
scaffolds for cell adhesion through thiol-yne photopolymerization.  We were able to form 
scaffolds in the presence of endothelial cells without affecting the viability of the cells.   
In Chapter 4, we modified the PEG derivatives synthesized in Chapter 3 to make them 
multifunctional PEG derivatives.  These PEG derivatives were synthesized to create more 
options for fabricating and functionalizing microspheres and scaffolds.  We fabricated 
microspheres, crosslinked them into scaffolds, and loaded them with VEGF.  They were shown 
to deliver VEGF without affecting its bioactivity.  Scaffolds were also modified with heparin to 
control the release of VEGF, but their ability to deliver VEGF effectively was inconclusive.  The 
scaffolds were fabricated in the presence of fibroblasts and endothelial cells to test their ability to 
support vascularization.  The scaffolds supported small regions of vascularization, but it was not 
as prominent as the vascular network found in fibrin gel controls.  With some modifications, 
these scaffolds hold a great deal of promise for vascularization in tissue engineering. 
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5.2 Future Directions 
 The modular microsphere-based PEG scaffolds presented in Chapter 4 are promising 
candidates for promoting vascularization.  Several improvements can be made to increase their 
vascularization potential.  While we demonstrated that the scaffolds did not affect the bioactivity 
of VEGF, the results from VEGF delivery from heparinated scaffolds were ambiguous.  One 
possibility was that there was not enough VEGF loaded into the heparinated microspheres 
because the heparin attached to the surface of the microspheres prevented adequate loading of 
the VEGF into the microspheres for release.  The heparinated microspheres could also have been 
adequately loaded with VEGF, but the amount of heparin attached on the microspheres 
prevented an adequate burst release of VEGF as found with scaffolds delivering VEGF without 
heparin.  A solution to this is to measure and compare VEGF release from scaffolds with and 
without heparin using an enzyme-linked immunosorbent assay (ELISA) and adjusting the 
amount of heparin attached to heparinated scaffolds to improve VEGF loading and delivery for 
endothelial cell migration.  Different VEGF loading times can be performed on heparinated 
microspheres, and VEGF release can be measured from scaffolds formed by those microspheres 
to determine what effect loading times have on burst and total VEGF release.  An ELISA can 
also be used to measure VEGF release from scaffolds with varying degrees of heparin 
incorporation to compare their burst release of VEGF to scaffolds without heparin.  These 
strategies will help promote vascularization by improving VEGF release from heparinated 
scaffolds. 
 In an effort to decrease the foreign body response we observed in Chapter 2, we removed 
BSA from the scaffolds loaded with S1P as presented in Chapter 4.  However, this had a 
 109 
 
 
negative effect on the delivery of S1P.  Since S1P has been shown to play an important role in 
vascularization, it is important to incorporate their delivery back into the scaffolds.  An 
alternative method for delivering S1P may be the use PLGA.  PLGA microparticles have been 
used for sustained delivery of S1P to promote angiogenesis and vascular maturation in mice (Qi, 
Okamoto et al. 2010).  Copolymers of PLGA-PEG have been synthesized as a drug delivery 
system by activating PLGA with EDC/NHS and conjugating it with the amine on COOH-PEG-
NH2 (Kumara, Sahoo et al. 2014; Kumar, Sahoo et al. 2015).  This technique can be modified to 
create PLGA-PEG microspheres that encapsulate S1P and crosslink via click reactions with PEG 
microspheres to form scaffolds.  The degradability of the PLGA-PEG microspheres could also 
control the release of S1P and increase the porosity of the scaffold over time, removing the need 
for additional porogenic microspheres.  Achieving delivery of S1P and VEGF simultaneously 
from the scaffold may increase the success of scaffold vascularization in vivo. 
 While the vascularization of scaffolds presented here is promising, more development 
must be done to produce optimal scaffolds.  One solution would be to increase scaffold porosity; 
however, this would be at the cost of scaffold stiffness.  A more promising approach is to 
incorporate degradable peptides and proteins into the scaffold to allow cell degradability. Matrix 
metalloproteinases (MMPs) have been shown to be produced by endothelial cells to degrade 
basement membranes for proliferation and migration during the process of angiogenesis (Zucker, 
Conner et al. 1995; Sang 1998; Lafleur, Handsley et al. 2002).  MMPs are a family of zinc-
dependent endopeptidases that degrade extracellular matrix (ECM) proteins, such as laminin, 
collagen, and fibronectin (Sang and Douglas 1996; Sang 1998).  Introduction of MMP 
degradable peptide and proteins into the structure of the scaffold would allow endothelial cells to 
break down scaffold to suit their needs.  This can also be achieved by making laminin an integral 
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part of the structure of the scaffolds.  For example, laminin can be conjugated to PEG to create 
PEG-laminin microspheres that can also crosslink with structural PEG microspheres in the 
presence of cells to form scaffolds.   Like the MMP degradable peptide, this will allow 
endothelial cells to degrade the scaffold to suit their needs. 
 Once these issues have been addressed and tested in vitro, the PEG microsphere scaffolds 
can be tested in vivo as was done in Chapter 2.  After these scaffolds successfully promote 
vascularization in vivo, the next step will be to apply them in scenarios that require development 
of a vascular network for cell and tissue survival.  Successful vascularization techniques will 
someday lead to better applications of tissue-engineered constructs and tissue implants.  The goal 
is that these applications will become reliable ways to replace or repair damaged and defective 
tissues.  
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